

Department of Pharmacology & Toxicology

# 2013 Annual Report



# **TABLE OF CONTENTS**

**DEPARTMENT PHOTO - 3** 

MISSION - 4

NEW FACULTY APPOINTMENTS AND TRANSERS – 5

FACULTY PROMOTIONS - 11

FACULTY RESIGNATIONS – 13

STAFF APPOINTMENTS AND RETIREMENTS - 14

FACULTY WITH PRIMARY APPOINTMENTS -15

FACULTY WITH SECONDARY APPOINTMENTS -19

FACULTY WITH EMERITUS AND ADJUNCT APPOINTMENTS - 28

**OFFICE STAFF -29** 

FACULTY HONORS – 29

**STUDENT HONORS - 31** 

**GRADUATES-32** 

**PUBLICATIONS - 34** 

ABSTRACTS - 40

**RESEARCH GRANTS ACTIVE - 51** 

**RESEARCH GRANTS SUBMITTED - 56** 

**INVITED SCIENTIFIC PRESENTATIONS - 61** 

**INTELLECTUAL PROPERTY ACTIONS – 64** 

**DEPARTMENTAL COURSES - 65** 

**STANDING COMMITTEES – 65** 

**DEPARTMENT GRADUATE STUDENTS – 67** 

PHD PARTNERSHIP WITH WENZHOU MEDICAL UNIVERSITY-67

**NEW GRADUATE STUDENTS** 

NCI CANCER EDUCATION PROGRAM STUDENTS



Department of Pharmacology and Toxicology-2013

# MISSION

The Department of Pharmacology and Toxicology is committed to academic excellence and to the attainment of regional, national, and international recognition for the quality of its educational, research, and service activities. Guided by the University of Louisville Strategic Plan (The 2020 Plan) to continue our path to national prominence, the mission of the Department of Pharmacology and Toxicology focuses on five broad objectives:

- Provide instruction in pharmacology and toxicology of the highest quality for the education and preparation of medical, dental, nursing, and other health care professional students. Emphasis is placed on the fundamental principles necessary for life-long learning and the essential knowledge required for rational, effective, and safe use of drug therapy.
- Advance biomedical knowledge through high quality research and other scholarly activities, particularly in pharmacology and toxicology and other areas of focus within the University of Louisville 2020 Plan.
- Provide high quality research and educational experiences in pharmacology and toxicology for the education and training of future biomedical scientists who will provide and advance biomedical education, research, and service.
- Provide instruction of the highest quality in pharmacology and toxicology that is appropriate for students at the undergraduate, graduate, and postgraduate levels.
- Provide high quality service to the School of Medicine, the Health Sciences Center, the University, the people of Louisville and the surrounding region, the Commonwealth of Kentucky, professional organizations, the nation, and the world.

# **NEW FACULTY APPOINTMENTS (Primary appointments)**



Leah J. Siskind, PhD was appointed Associate Professor of Pharmacology & Toxicology, tenure track, effective July 1, 2013. Dr. Siskind obtained her BS in neurobiology and physiology and her PhD in biology from the University of Maryland. She subsequently completed postdoctoral training at the University of Maryland and the Medical University of South Carolina. She was appointed assistant professor (research) of medicine at the Medical University of South Carolina subsequently Assistant Professor on the tenure track in the Department of Drug Discovery and Biomedical Sciences in the South Carolina College of Pharmacy at the Medical University of South Carolina. In addition, she held appointment as a Research Health Scientist in the Veterans Administration. The overall goal of her research program is to understand more precisely the role of specific sphingolipids in disease and to identify and develop novel therapeutics. Her research expertise includes lipidomics, membrane biophysics, mitochondrial bioenergetics, cellular and molecular biology, and sphingolipid biochemistry. She is the principal investigator on a large five year NIH R01 grant entitled "Role of ceramide-induced kidney cell death in acute kidney injury that transfered to the University of Louisville upon her appointment.



**J. Christopher States, PhD,** Professor of Pharmacology and Toxicology was appointed Associate Dean for Research in the School of Medicine effective December 1, 2013.

# FACULTY TRANSFER



**Geoffrey J. Clark, PhD** transferred from the Department of Medicine to Associate Professor of Pharmacology & Toxicology with tenure, effective August 1, 2013. Dr. Clark received his PhD in Molecular Oncology from the University of Manchester. Following postdoctoral fellowships at the University of Southern California, the La Jolla Cancer Research Foundation, and the University of North Carolina, he was appointed Research Assistant Professor in the Department of Pharmacology at the University of North Carolina. He was then recruited to the National Cancer Institute where he served as Head of the Signaling and Oncogenesis Laboratory in the Cell and Cancer Biology Branch prior to his recruitment to the UofL's James Graham Brown Cancer Center Molecular Targets Program in 2006. He has developed a robust cancer research program and has been very successful in obtaining extramural funding support for his research program, including a prestigious NIH R01 Eureka Award.

# FACULTY EMERIUS APPOINTMENTS



**Theresa S. Chen, PhD** Appointed Professor Emerita effective July 1, 2013



Walter M. Williams, MD, PhD Appointed Professor Emeritus effective July 1, 2013

# **NEW FACULTY APPOINTMENTS (Secondary appointments)**




**Shesh N. Rai, PhD** Professor of Bioinformatics and Biostatistics, effective July 1, 2013



**Yi Tan, PhD** Assistant Professor of Pediatrics, effective July 1, 2013



Michael L. Merchant, PhD Associate Professor of Medicine, effective July 1, 2013



**Jun Yan, MD, PhD** Professor of Medicine, effective September 1, 2013



**Jill M. Steinbach, PhD** Assistant Professor of Bioengineering, effective October 1, 2013



**Robert C.G. Martin, MD, PhD** Professor of Surgery, effective September 1, 2013



Sanjay Srivastava, PhD Professor of Medicine, effective November 1, 2013



Xiang Zhang, PhD Professor of Chemistry, effective December 1, 2013

# FACULTY PROMOTIONS



**Nobuyuki Matoba, PhD,** was promoted to Associate Professor of Pharmacology and Toxicology with tenure effective January 1, 2014.



**Uma Sankar, PhD,** was promoted to Associate Professor of Pharmacology and Toxicology, with tenure effective January 1, 2014.



Guy N. Brock, PhD, was promoted to Associate Professor of Bioinformatics and Biostatistics.



Lu Cai, MD, PhD, was promoted to Professor of Pediatrics.




Jason A. Chesney, MD, PhD, was promoted to Professor of Medicine effective June 1, 2013.

# FACULTY RESIGNATIONS



**Teresa Whei-Mei Fan, PhD** professor of Chemistry resigned August 31, 2013 to accept a position as Professor of Toxicology and Cancer Biology at the University of Kentucky.



**Theo Hagg, MD, PhD, professor Neurological Surgery** resigned December 31, 2013 to accept the position as Chair of the Department of Biomedical Sciences at East Tennessee State University.

# STAFF APPOINTMENTS



**Florence Su** Administrative Assistant, effective May 3, 2013

# STAFF RETIREMENTS



**Sharon Carpenter** Administrative Assistant, effective May 31, 2013



Heddy Rubin-Teitel Administrative Assistant, effective December 31, 2013

# FACULTY WITH PRIMARY APPOINTMENTS

## Gavin E. Arteel, PhD

Professor and Associate Chair for Research Ph.D., Toxicology, University of North Carolina-Chapel Hill (1997)

**Research Interests:** Mechanisms of oxidative stress; mechanisms of alcohol-induced hepatitis, pancreatitis, and hepatocellular carcinoma.

#### Juliane I. Arteel, PhD (Juliane Beier in professional publications)

Assistant Professor of Pharmacology & Toxicology Ph.D., Biochemistry and Molecular Biology, Heinrich-Heine-Universität (2005)

**Research Interests:** Interactions of diet and environmental toxins in the production of nonalcoholic fatty liver disease.

**Frederick W. Benz, PhD** Professor Ph.D., Pharmacology, University of Iowa (1970)

**Research Interests:** Biochemical pharmacology and toxicology; biochemical mechanisms of drug action and toxicity.

#### Brian P. Ceresa, PhD

Associate Professor of Pharmacology & Toxicology PhD, Pharmacology, Vanderbilt University (1995)

**Research Interests:** Membrane trafficking and signaling of the epidermal growth factor receptor (EGFR); the EGFR is overexpressed and hyperactivated in many cancers; our goal is to better understand how signaling by this receptor is regulated with the goal of attenuating its signaling in cancer.

## **Theresa S. Chen, PhD** Professor Ph.D., Pharmacology, University of Louisville (1971)

**Research Interests:** Biochemical toxicology; role of glutathione in aging toxicology; general and specific toxicity of environmental pollutants

#### Geoffrey J. Clark, PhD

Associate Professor of Pharmacology & Toxicology Ph.D., Molecular Oncology, University of Manchester (1989)

**Research Interests:** Role of RAS oncogenes and RASSF family of tumor suppressors in cancer etiology; development of oncopig model for human cancer; and the identification and development of novel small molecules for cancer therapy.

#### Keith R. Davis, PhD

Professor Ph.D., Molecular, Cellular and Developmental Biology, University of Colorado (1985)

**Research Interests:** Development of plant-made pharmaceuticals; activation of gene expression by oxidative stress; and the role of innate immunity in cancer initiation and progression.

#### Ramesh C. Gupta, PhD

Professor and Agnes Brown Duggan Chair of Oncological Research Ph.D. Analytical/Physical Chemistry, University of Roorkee (1972)

**Research Interests**: Development and identification of intermediate biomarkers to investigate etiology and prevention of human cancers resulting from both environmental and endogenous exposures.

#### David W. Hein, PhD

Professor and Peter K. Knoefel Chair of Pharmacology and Toxicology Ph.D., Pharmacology, University of Michigan (1982)

**Research Interests:** Molecular pharmacogenetics; molecular epidemiology; functional genomics; genetic predisposition to chemical carcinogenesis and drug toxicity; molecular genetics; and environmental toxicology

# Harrell E. Hurst, PhD

Professor Ph.D., Toxicology, University of Kentucky (1978)

**Research Interests:** Analytical toxicology and kinetics with emphasis on qualitative and quantitative techniques, including gas chromatography, high pressure liquid chromatography and GC/mass spectrometry

**Y. James Kang, PhD** Professor Ph.D., Cell Biology and Zoology, Iowa State University (1989)

**Research Interests:** Molecular and cardiac toxicology; transgenic and knock-out animal models to study oxidative injury and antioxident systems in the heart; biological functions and toxicological significance of metallothionein and glutathione in vivo

## La Creis R. Kidd, PhD, MPH

Associate Professor and Our Highest Potential Endowed Chair in Cancer Research Ph.D., Toxicology, Massachusetts Institute of Technology (1997)

**Research Interests:** Gene-gene and gene-environmental interactions; polymorphic xenobiotic metabolizing enzymes and prostate cancer susceptibility; and cancer health disparities

## Igor S. Lukashevich, MD, PhD, DSci

Professor of Pharmacology & Toxicology
M.D., Minsk Medical Institute, Belaris (1973)
Ph.D., Institute of Virology, Academy of Medical Science, Moscow Russia (1976)
D.Sc., Institute of Virology, Academy of Medical Science, Moscow Russia (1987)

**Research Interests:** Novel vaccine technologies (virus-like-particle vectors; reassortant vaccines, infectious DNA vaccination); molecular biology and pathogenesis of viral hemorrhagic fevers

# Nobuyuki Matoba, PhD

Associate Professor Ph.D., Applied Life Sciences, Kyoto University, Japan (2001)

**Research Interests:** Development of vaccines and antivirals; mucosal immune response to foreign substances; and plant biotechnology for human health

# Steven R. Myers, PhD

Associate Professor Ph.D., Pharmacology, University of Kentucky (1986).

**Research Interests:** Drug metabolism; metabolism of xenobiotics and chemical carcinogens; use of hemoglobin as biomarker in exposure to xenobiotics

**Donald E. Nerland, PhD** Professor Ph.D., Medicinal Chemistry, University of Kansas (1974).

Research Interests: Biochemical toxicology; metabolism of drugs and environmental pollutants

**Kenneth E. Palmer, PhD** Professor Ph.D., Microbiology, University of Cape Town (1997)

**Research Interests:** Development of vaccines and antiviral proteins to prevent and treat viral diseases that predispose people to development of cancer

## William M. Pierce Jr, PhD

Professor and Executive Vice President for Research and Innovation Ph.D., Pharmacology and Toxicology, University of Louisville (1981).

**Research Interests:** Mechanisms of bone formation and resorption; design of novel drugs for management of osteoporosis; biomolecular mass spectrometry; proteomics in structural biology

#### Peter P. Rowell, PhD

Professor and Vice Chair for Graduate Education Ph.D., Pharmacology and Therapeutics, University of Florida (1975).

**Research Interests:** Neuropharmacology; effect of drugs on brain neurotransmitters and receptors

#### Uma Sankar, PhD

Associate Professor Ph.D., Molecular, Cellular, and Developmental Biology, Ohio State University (2003).

**Research Interests:** Role of calcium/calmodulin-dependent protein kinase signaling in hematopoetic stem cell biology and cancer

# Leah J. Siskind, PhD

Associate Professor Ph.D., Biology, University of Maryland (2003)

**Research Interests:** Role of sphingolipids in regulating cellular processes such as apoptosis, necrosis, proliferation, and inflammation in the context of disease states; Design of drugs to rebalance sphingolipid metabolism and improve disease outcomes

**Zhao-Hui (Joe) Song, PhD** Professor Ph.D., Pharmacology, University of Minnesota (1992).

**Research Interests:** Molecular pharmacology; cloning and functional characterization of novel G protein-coupled receptors; molecular mechanisms of action and structure-function relationships of cannabinoid (marijuana) receptors

# J. Christopher States, PhD

Professor and Graduate Director: Recruitment and Admissions Ph.D., Molecular Biology and Pathology, Albany Medical College/Union University (1980).

**Research Interests:** Molecular biology and molecular genetics of DNA damage and repair in humans; mechanisms of chemoresistance; arsenic toxicity and cell cycle disruption

Walter M. Williams, MD, PhD

Professor Ph.D., Pharmacology, University of Louisville (1970); M.D., University of Louisville (1974).

Research Interests: Studies of drug elimination (metabolism and excretion).

# FACULTY WITH SECONDARY APPOINTMENTS

**George R. Aronoff, MD** Professor of Medicine M.D., Indiana University (1975)

**Research Interests:** Effects of uremia on drug disposition in humans; drug nephrotoxicity and renal drug metabolism, artificial intelligence.

**Shirish Barve, PhD** Professor of Medicine Ph.D., Molecular Pathogenesis, University of Kentucky (1990)

**Research Interests:** Effects of alcohol on molecular mechanisms of cytokine action, gene expression and liver injury.

#### Levi J. Beverly, PhD

Assistant Professor of Medicine (Division of Hematology and Oncology) Ph.D., Molecular Biology, Biochemistry, and Microbiology, University of Cincinnati (2007)

Research Interests: Regulation of anti-apoptotic proteins in cancer progression and treatment.

#### Aruni Bhatnagar, PhD

Professor of Medicine Ph.D., Chemistry, University of Kanpur (1985)

**Research Interests:** Cardiovascular toxicology; oxidative mechanisms of cardiovascular disease; lipid peroxidation in atherosclerosis; gene expression; secondary complications of diabetes.

## Haribabu Bodduluri, PhD

Professor of Microbiology & Immunology Ph.D., Biochemistry, Indian Institute of Science (1983)

**Research Interests:** Signal transduction and chemoreceptors; role of leukotriene receptors in inflammation and host response.

Michael E. Brier, PhD Professor of Medicine Ph.D., Industrial and Physical Pharmacy, Purdue University (1986)

Research Interests: Clinical pharmacokinetics/dynamics; Drug dosing in renal failure.

## **Guy N. Brock, PhD Associate Professor of Bioinformatics and Biostatistics** PhD. Statistics, University of New Mexico (2003)

**Research Interests:** Methodological research in statistical bioinformatics and statistical genetics, with emphasis on cluster validation, missing value imputation, and classification for high-throughput data. Main areas of clinical and collaborative research include transplantation, liver disease, community acquired pneumonia, genetic variants related to breast and prostate cancer, and the molecular determinants of developmental defects during the neural tube and secondary palate formation.

#### **Jian Cai, PhD** Assistant Professor of Medicine Ph.D., Pharmacology and Toxicology, University of Louisville (1999)

**Research Interests:** Application of mass spectrometry in biomedical research; Drug and metabolite identification and quantification; Protein identification and post-translational modification; Hemoglobin adducts as biomarkers of chemical exposure and pathogenesis.

#### Lu Cai, MD, PhD

Professor of Pediatrics and Radiation Oncology Ph.D., Radiation Biology/Oncology, Norman Bethune University of Medical Sciences (1987)

Research Interests: Diabetic cardiomyopathy and nephropathy

#### Matthew C. Cave, MD

Assistant Professor of Medicine (Division of Gastroenterology, Hepatology, and Nutrition) M.D., University of Kentucky (2001)

**Research Interests:** Steatohepatitis and liver cancer related to environmental and occupational chemical exposures; Complementary and alternative medicine in liver disease; Alcoholic and nonalcoholic fatty liver disease; Treatment of Hepatitis C.

Jason A. Chesney, MD, PhD Professor of Medicine Ph.D., Biomedical Sciences/Immunology, University of Minnesota (1997) M.D., University of Minnesota (1998)

**Research Interests:** Novel regulators of cancer cell metabolism; identification of emerging viruses and the development of immune-based therapies against widely metastatic cancers.

#### Daniel J. Conklin, PhD

Associate Professor of Medicine (Cardiology) Ph.D., University of Notre Dame (1995)

Research Interests: Environmental cardiology; cardiovascular toxicology

#### Albert R. Cunningham, PhD

Associate Professor of Medicine Ph.D., Environmental and Occupational Health, University of Pittsburgh (1998)

**Research Interests:** Structure-Activity Relationship Modeling: Carcinogens, Chemotherapeutics, and Molecular Targets.

#### John W. Eaton, PhD

James Graham Brown Professor of Medicine Ph.D., Biological Anthropology and Human Genetics, University of Michigan (1969)

**Research Interests:** Biological oxidation/reduction reactions with special emphasis on inflammatory diseases and neoplasia.

#### Paul N. Epstein, PhD

Professor of Pediatrics Carol B. McFerran Chair in Pediatric Diabetes Research Ph.D., Pharmacology, Baylor College of Medicine (1981)

**Research Interests:** Molecular mechanisms of diabetogenesis. The use of transgenic animals to study genetics and molecular mechanisms in vivo.

#### Wenke Feng, PhD

Assistant Professor of Medicine (Division of Gastroenterology, Hepatology, and Nutrition) Ph.D, Biochem/Biotech, University for Bodenkultur, Vienna, Austria (1998)

**Research Interests:** Mechanisms of alcoholic liver disease; Mechanisms of nonalcoholic steatohepatitis; Tissue hypoxia and diabetic complications

#### Hermann B. Frieboes, PhD

Assistant Professor of Bioengineering Ph.D., Biomedical Engineering, University of California, Irvine (2006)

**Research Interests:** 1) Develop and apply realistic, predictive biocomputational models integrated with clinical and laboratory data to study cancer growth and treatment; 2) Design of patient-specific therapies; and 3) Design of multiscale biocomputational models to describe the complex interaction between cancer treatment and the immune system.

#### **Evelyne Gozal, PhD**

Associate Professor of Pediatrics Ph.D., Toxicology, University of Southern California (1997)

**Research Interests:** Signal transduction pathways involved in neuronal cell survival and neuronal cell death during hypoxia; cellular mechanisms underlying brain adaptation to chronic and intermittent hypoxia; identification of the kinases and transcription factors activated by hypoxia, leading to gene induction and to adaptation to oxygen deprivation.

#### Yiru Guo, MD

Associate Professor of Medicine (Division of Cardiovascular Medicine) M.D., Xinjiang Medical University (1982)

**Research Interests:** Cardio-thoracic and vascular surgery, physiology, and pharmacology. Research focuses on: (i) elucidating the mechanisms of ischemic- pharmacologic- and exerciseinduced preconditioning by using the ischemia/reperfusion model in genetically engineered animals, (ii) studying protection of ischemic myocardium by using gene and/or cell therapy, and (iii) elucidating adaptations to ischemia/reperfusion injury in the aging heart.

#### Theo Hagg, MD, PhD

Professor & Endowed Chair of Neurological Surgery M.D., University of Leiden (1985) Ph.D., Neurosciences, University of California-San Diego (1998)

**Research Interests:** Neurotrophic factor receptors and endogenous stem cells as drug targets to develop repair strategies for neurological disorders, including spinal cord injury.

#### Michal Hetman, MD, PhD

Associate Professor of Neurological Surgery Endowed Professor of Molecular Signaling M.D., Warsaw Medical School (1994) Ph.D., Experimental and Clinical Medicine, Polish Academy of Sciences (1997)

Research Interests: Role of signaling kinases in neuronal repair and demise.

#### Ben Jenson, MD

Professor and Senior Scientist, James Graham Brown Cancer Center M.D., Baylor College of Medicine (1966)

**Research Interests:** Translational immunology: humoral responses to prevent infection by papillomavirus.

#### Steven P. Jones, PhD

Associate Professor of Medicine (Division of Cardiovascular Medicine) Ph.D., Physiology, Louisiana State University Health Sciences Center, Shreveport (2002)

Research Interests: Metabolic signaling in the cardiovascular system

#### Colleen B. Jonsson, PhD

Professor of Microbiology and Immunology Ph.D., Biochemistry, Purdue University (1990)

**Research Interests:** Molecular virology of emerging negative-strand RNA viruses; natural history, ecology, evolution and treatment.

#### Swati Joshi-Barve, PhD

Assistant Professor of Medicine (Division of Gastroenterology, Hepatology, and Nutrition) Ph.D., Biochemistry, University of Kentucky (1992) **Research Interests:** Mechanisms of Steatohepatitis (nonalcoholic and alcoholic fatty liver disease); Mechanisms of Alcohol-induced Immune Dysfunction; Mechanisms of Hepatocellular Carcinoma.

#### Brad B. Keller, MD

Professor of Pediatricsand Bioengineering Kosair Charities Chair and Chief, Division of Pediatric Heart Research M.D., Pennsylvania State University (1985)

**Research Interests:** Cardiovascular bioengineering: Development of 3D tissues for heart repair and regeneration.

#### Chi Li, PhD

Assistant Professor of Medicine Ph.D, Molecular Biology, Columbia University (1998)

**Research Interests:** Mechanisms of apoptotic pathways initiated from different intracellular organelles. Molecular and cellular mechanisms that affect inflammation and immunity.

#### **Robert C. G. Martin, MD**

Professor and Sam and Lolita Weakley Endowed Chair in Surgical Oncology M.D., University of Louisville (1995) Ph.D., Pharmacology & Toxicology, University of Louisville (2008)

**Research Interests:** Genetic predisposition to cancer

#### Craig J. McClain, MD

Professor of Medicine M.D., University of Tennessee-Memphis (1972)

**Research Interests:** Role of cytokines in liver injury and other forms of hepatotoxicity, interactions with nutrition and toxicology.

#### Kelly M. McMasters, MD, PhD

Sam and Lolita Weakley Endowed Professor of Surgical Oncology Ph.D., Cell and Developmental Biology, Rutgers University (1988) M.D., University of Medicine and Dentistry of New Jersey (1989)

**Research Interests:** Adenoviral vector cancer gene therapy; Development of vectors that selectively replicate in cancer cells; Mechanisms of E2F-1-induced apoptosis.

#### Lacey R. McNally, PhD

Assistant Professor of Medicine (Division of Hematology and Oncology) PhD, Veterinary Medical Science, Louisiana State University (2004) **Research Interests:** Metastasis suppressors, such as KISS1, as a method for preventing and treating metastatic pancreatic and ovarian cancers; Mechanisms of chemotherapy resistance and alternative treatment for macro-metastasis and recurrence in ovarian and prostate cancers; Mechanisms involved in organ specific metastasis of pancreatic, prostate, and breast cancers

## Michael L. Merchant, PhD

Associate Professor of Medicine (Division of Nephrology and Hypertension) PhD, Chemistry, University of Arkansas (1994)

**Research Interests:** Translational research - the discovery and understanding of biomarkers of renal disease; Basic Research - Mechanisms of renal function decline and fibrosis; Basic Research - Mechanisms for the transition from acute to chronic disease

## Chin K. Ng, PhD

Associate Professor of Radiology Ph.D., Medical Physics, University of Wisconsin (1989)

**Research Interests:** Development, evaluation, and kinetic studies of radiopharmaceuticals; the use of molecular imaging for biomedical research.

## Timothy E. O'Toole, PhD

Assistant Professor of Medicine (Division of Cardiovascular Medicine) Ph.D., Biological Chemistry, University of Michigan (1987)

**Research Interests:** Function and regulation of the endothelium in various disease states; Role of miRNA in endothelial regulation towards understanding how diabetic conditions and pollutant exposure affects endothelial miRNA content and the consequent changes in protein expression levels and cellular function.

#### Donald M. Miller, MD, PhD

James Graham Brown Professor of Medicine M.D., Duke University (1973); Ph.D., Biochemistry, Duke University (1973)

**Research Interests:** Molecular and clinical oncology; modulation of oncogene expression; triplex DNA based gene therapy; treatment of melanoma.

#### M. Michele Pisano, PhD

Professor of Molecular, Cellular and Craniofacial Biology Ph.D., Anatomy, Thomas Jefferson University (1985)

**Research Interests:** Molecular developmental toxicology; gene-environment interactions in normal and abnormal embryonic development; growth factor directed cellular signal transduction in embryonic cell growth and differentiation.

#### Shesh N. Rai, PhD

Professor of Bioinformatics and Biostatistics; Wendell Cherry Chair in Clinical Trial Research Ph.D., Statistics, University of Waterloo (1993)

**Research Interests:** Clinical Trials, Survival Analysis, Bioinformatics, Mixed Effects Model, Sample Survey, Quantitative Risk Assessment

# George C. Rodgers, MD, PhD

Professor of Pediatrics; Humana Chair of International Pediatrics Ph.D., Organic Chemistry, Yale University (1964); M.D., State University of New York (1975).

**Research Interests:** Toxicokinetics in drug overdoses and pharmacokinetics in pediatric disease states.

#### Jesse Roman, MD

Professor and Chair of Medicine M.D., University of Puerto Rico School of Medicine (1983)

**Research Interests:** Extracellular matrices and integrin receptors in lung development, injury, and repair; Role of nicotinic acetylcholine receptors and control of matrix expression in lung; Lung tissue remodeling in tobacco- and ethanol-related lung disorders; Control of lung carcinoma growth by extracellular matrices.

#### David A. Scott, PhD

Associate Professor of Oral Immunology & Infectious Diseases Ph.D., Microbiology and Immunology, McGill University (1997)

**Research Interests:** Tobacco-induced alterations to microbial-associated molecular patterns of Porphyromonas gingivalis; Tobacco-induced alterations to innate-pathogen interactions; Tobacco alkaloid amplification of endogenous anti-inflammatory pathways; Identification of gingivitis- and periodontitis-specific infrared molecular signatures

#### Sanjay Srivastava, PhD

Professor of Medicine (Cardiology) Ph.D., Chemistry, University of Lucknow (1993)

**Research Interests:** Delineating the mechanisms by which environmental pollutants cause endothelial activation, vascular inflammation, insulin resistance and atherosclerosis.

#### Jill M. Steinbach, PhD

Assistant Professor of Bioengineering Ph.D., Biomedical Engineering, Arizona State University (2009)

**Research Interests**: Design and development of drug and gene delivery vehicles for physiologically difficult-to-deliver-to microenvironments.

#### Yi Tan, PhD

Assistant Professor of Pediatrics Ph.D., Biomedical Engineering, Chongqing University (2004)

**Research Interests:** Signaling pathways and therapeutic strategies in diabetic complications including cardiomyopathy, cardiac insulin resistance, stem cell mobilization and ischemic angiogenesis.

#### David J. Tollerud, MD

Professor and Chair of Environmental and Occupational Health Sciences M.D., Mayo Medical School (1978); M.P.H., Harvard Medical School (1990)

**Research Interests:** Occupational and environmental health; Occupational toxicology; molecular epidemiology.

#### Janice E. Sullivan, MD Professor of Pediatrics

M.D., University of Minnesota (1988)

**Research Interests:** Clinical pharmacology with a focus on developmental pharmacokinetics and pharmacodynamics.

# Brian (Binks) W. Wattenberg, PhD

Associate Professor of Medicine Ph.D., Biological Chemistry, Washington University (1981)

Research Interests: Sphingosine-kinase and lipid signaling. Trafficing of tail-anchored proteins.

# Jun Yan, MD, PhD

Professor of Medicine and Endowed Chair in Translational Research M.D., Jiangsu University School of Medicine (1985) Ph.D., Immunology, Shanghai Jiaotong University School of Medicine (1997)

**Research Interests:** Immunotherapy and vaccines for treatment of cancer and infectious diseases

#### Hong Ye, PhD Associate Professor of Medicine Ph.D., Biophysics, Keele University (1998)

**Research Interests:** Research to understand the structure and mechanism of tumorgenesis, with focus on Notch signaling pathway and chromosome DNA damage; X-ray crystallography, in combination with other biochemical and biophysics methods to understand the function of various molecular complexes.

#### Walter H. Watson, PhD

Assistant Professor of Medicine (Division of Gastroenterology, Hepatology and Nutrition) Ph.D. Toxicology, University of Kentucky (1999)

**Research Interests:** Oxidative stress and redox signaling; Mechanistic toxicology; Alcoholic and nonalcoholic fatty liver disease.

**Wolfgang Zacharias, PhD** Professor of Medicine Ph.D., Biochemistry, Philipps-University, Marburg, Germany (1980)

**Research Interests:** Ribozymes for gene therapy in rheumatoid arthritis; involvement and roles of cathepsins in oral cancers; gene expression profiling with DNA microarray chip technology.

#### **Xiang Zhang, PhD**

Professor of Chemistry Ph.D., Bioanalytical Chemistry, Purdue University (2001)

**Research Interests:** Molecular systems biology, by exploiting practical and efficient highthroughput technologies for analyses of complex mixtures to facilitate the development of preventive, predictive and personalized medicine for the promotion of health and wellness.

# FACULTY WITH EMERITUS APPOINTMENTS

- Carr, Laurence A., Professor Emeritus; Ph.D., Michigan State University (1969).
- Chen, Theresa, Professor Emerita; Ph.D., University of Louisville (1971).
- Dagirmanjian, Rose, Professor Emerita; Ph.D., University of Rochester (1960).
- **Darby, Thomas D.**, Professor Emeritus; Ph.D., Medical College of South Carolina (1957).
- Jarboe, Charles H., Professor Emeritus; Ph.D., University of Louisville (1956).
- Waddell, William J., Professor and Chair Emeritus; M.D., University of North Carolina (1955).
- Waite, Leonard C., Professor Emeritus, Ph.D., University of Missouri (1969).
- Williams, W. Michael, Professor Emeritus, Ph.D., University of Louisville (1970); M.D., University of Louisville (1974).

# FACULTY WITH ADJUNCT APPOINTMENTS

- James A. Blank, Adjunct Associate Professor of Pharmacology and Toxicology; PhD, Pharmacology and Toxicology, University of Louisville School of Medicine (1985).
- Adrian J. Fretland, Adjunct Assistant Professor of Pharmacology and Toxicology; PhD, Pharmacology and Toxicology, University of Louisville School of Medicine (2000).
- John C. Lipscomb, Adjunct Associate Professor of Pharmacology and Toxicology; PhD, Pharmacology and Toxicology, University of Arkansas for Medical Sciences (1991).
- **Kristin J. Metry-Baldauf**, Adjunct Assistant Professor of Pharmacology and Toxicology; PhD, Pharmacology and Toxicology, University of Louisville School of Medicine (2007).
- Eric M. Vela, Adjunct Assistant Professor of Pharmacology and Toxicology; PhD, Virology and Gene Therapy, University of Texas Health Sciences Center at Houston (2005)

# **OFFICE STAFF**

Carpenter, Sharon	Administrative Assistant		
Greca, Edie	Unit Business Manager		
McClain, Marion	Research Facilitator (Primary appointment in Department of		
	Medicine; Part time in Department of Pharmacology and		
	Toxicology)		
Rubin-Teitel, Heddy	Administrative Assistant		
Su, Florence	Administrative Assistant		
Tatum, Shiloh	Unit Business Manager (Primary appointment in Department of		
	Medicine; Part time in Pharmacology and Toxicology)		

# **FACULTY HONORS**

# Arteel, Gavin:

- Received the Jewish Hospital & St. Mary's Foundation Basic Research Faculty Award at Research!Louisville
- Protégé (Massey VL), Ohio Valley Society of Toxicology annual meeting. Abstract selected for a platform presentation; 1<sup>st</sup> place student award
- Most promising basic research faculty award, 1<sup>st</sup> place, Research!Louisville
- Co-author (Ramakrishnan VM) Research!Louisville; 2<sup>nd</sup> place Medical Student Poster Award)

# Arteel, Juliane Beier:

• 2013 Member of the AASLD Education Committee

# Gupta, Ramesh:

- Special recognition by the University of Louisville President for issuance of Dr. Gupta's patented technology as an Option Agreement to 3P Biotechnologies, September 9, 2013
- A special Symposium titled "Technologies in Carcinogenesis and Cancer Chemoprevention" was held (May 30-31) in honor of Dr. Gupta's 65<sup>th</sup> birthday, organized by Drs. Ravi Kumar and Vadhanam. Over 20 invited speakers from the U.S., England and India were the speakers; the symposium was also accompanied by a Special Issue on the subject, published by *Cancer Letters*

# Hein, David:

- Appointed Visiting Professor at Wenzhou Medical University
- Summer student (Neil Bodduluri) selected for third place poster presentation award at Research!Louisville
- Graduate student (Marcus Stepp) selected for oral research presentation at annual meeting of the Ohio Valley Society of Toxicology

# Hurst, Harrell:

• Recognition for 35 years of faculty service, University of Louisville

# Kidd, LaCreis:

- 2004-present: "Our Highest Potential" Endowed Chair in Cancer Research, James Graham Brown Cancer Center, University of Louisville (UofL), School of Medicine
- Student—Dominique Jones: 2012-2015: \$20,000 Southern Regional Education Board Doctoral Scholars Award 2011-2012: Integrated Programs in Biomedical Sciences Fellowship (IPIBS), UofL 2012: Golden Key International Honor Society for having a ≥ GPA 3.5

# Lukashevich, Igor:

• University Scholar, 2011-present

# McClain, Craig:

• Selected as the 2013 recipient of the Elizabeth Hurlock Beckman Award, a very prestigious national award for mentoring

# Sankar, Uma:

- NIH Early Career Reviewer
- American Cancer Society Research Scholar
- ASBMR Young Investigator Travel Award for graduate student Zack Pritchard
- Pritchard Z, Cary, R, Novack D, Voor M and Sankar U. CaMKK2 Inhibition as a Novel Bone Anabolic Strategy in the Prevention of Post-Menopausal and Therapy-Induced Osteoporosis 35<sup>th</sup> Annual Meeting of the American Society for Bone and Mineral Research, October 4-7, 2013, Blatimore, MD. Was selected to be presented as a Plenary Poster on October 4 and 5, and graduate student Zack Pritchard won a Young Investigator Travel Award for the meeting.

## States, J. Christopher:

• Student—Douglas J. Saforo, Pfizer Undergraduate Student Travel Award

# Tan, Yi:

• Received the Young Faculty Investigator Award at Research!Louisville

# **STUDENT HONORS**

**Samantha Barry** (**Kelly McMasters**, mentor) received the 1<sup>st</sup> place National Cancer Institute Outstanding Cancer Research Presentation Award in the professional student category at Research!Louisville.

**Srineil Bodduluri (David Hein**, mentor) and **Cameron Campbell (Ramesh Gupta,** mentor) received the 3<sup>rd</sup> place National Cancer Institute Outstanding Cancer Research Presentation Award in the undergraduate student category at Research!Louisville.

**Smita Ghare** (Shirish Barve, mentor) received the 1<sup>st</sup> place Postdoctoral Fellow Research Associate Award at Research!Louisville.

**Justin Huang** (Lacey McNally, mentor) received the 1<sup>st</sup> place Master's Basic Science Graduate Student award at Research!Louisville.

**Sean Shannon** (**Levi Beverly**, mentor) received the 2<sup>nd</sup> place National Cancer Institute Outstanding Cancer Research Presentation Award in the professional student category at Research Louisville.

**Stephen Wechman** (Kelly McMasters, mentor) received the 3<sup>rd</sup> place Master's Basic Science Graduate Student Award at Research!Louisville.

**Ray Yeager** (**Daniel Conklin**, mentor) received the Public Health and Information Sciences Research & Practice in Public Health Award at Research Louisville.

# **OHIO VALLEY SOCIETY OF TOXICOLOGY (OVSOT) AWARDS**

Melissa Skibba (Lu Cai, mentor) received the M.S. poster award.

**Banrida Wahlange** (Matt Cave, mentor) received the PhD Platform Presentation Award and was named the next student representative.

Veronica L. Massey (Gavin Arteel, mentor) received the Battelle minority/woman student award.

Natasha DeJarnett (Aruni Bhatnagar, mentor) received the Post-doc Poster Award.

**Smita Ghare** (Shirish Barve, mentor) was awarded the Post-doc Platform Presentation Award and was named the next post-doc representative.

# KC HUANG OUTSTANDING STUDENT AWARDS

## Colins O. Eno (Chi Li, mentor)

**Dissertation:** The role of endogenous Bcl-xL in regulation of apoptotic signaling pathways.

# Akshata Moghe (Shirish Barve, mentor)

**Dissertation:** The role of chromatin remodeling in curcumin-mediated regulation of gene expression in hepatocellular carcinoma.

# **2013 GRADUATES**

Graduate	Degree	Mentor	Dissertation/Thesis Title
Pei-Hsin (Penny) Cheng	Ph.D.	Kelly M. McMasters M.D., Ph.D.	Cyclin E induction and oncolytic replication of E1B-deleted adenoviruses
Amanda B. Lasnik	M.S.	Kenneth E. Palmer, Ph.D.	Preclinical safety assessment of griffithsin-based baginal microbicides

Alex C. Belshoff	Ph.D.	Teresa Fan, Ph.D.	Probing the anti-cancer mechanism of selenite: a metabolic approach
Robin H. Schmidt	Ph.D.	Gavin E. Arteel, Ph.D.	Olanzapine-induced liver injury: direct metabolic effects, exacerbation by high- fat diet, and protection with sulforaphane
Christopher G. England	M.S.	Hermann B. Frieboes, Ph.D.	Optimization of drug uptake into solid tumors using an integrated experimental/computational modeling approach
Glenn W. Vicary	M.S.	Jesse Roman, M.D.	The role of α7 nicotinic acetylcholine receptors in lung injury and repair

## **PHARMACOLOGY & TOXICOLOGY PUBLICATIONS** Faculty with Primary Appointments and Students

**1. Al-Maqtari T,** Sankar U. Approaches in the treatment of Parkinson's disease: A review of the main approaches in the treatment of Parkinson's disease with a focus on stem cell-based therapies. Lambert academic publishing house online, 2013

2. Arteel GE. Heme oxygenase and hepatic microcirculation: more than just carbon monoxide? *Digestion*. 2013, 87:100-101

3. Arteel GE. Build a better mouse model and the world will beat a path to your door. *Hepatology*, 2013,58:1526-28.

4. Beverly LJ, Howell LA, Hernandez-Corbacho MJ, Casson L, Chipuk JE, and Siskind LJ. BAK activation is necessary and sufficient to drive ceramide synthase-dependent ceramide accumulation following inhibition of BCL2-like proteins. *Biochem. J.*, 2013,452(1):111-9

5. Camp JV, Chu Y-K, Chung D-H, McAllister RC, Adcock RS, Gerlach RL, Weimkin TL, Peyrami P, Ramirez JA, Summersgill JT, Jonsson CB. Phenotypic Differences in Virulence and Immune Response in Closely Related Clinical Isolates of Influenza A 2009 H1N1 Pandemic Viruses in Mice. PLoS ONE, 2013, 8(2): e56602. doi:10.1371/journal.pone.0056602

6. Cary RL, Waddell S., Novack DN, Long F, Voor MJ, Sankar U. 2013. Inhibition of CaMKK2 stimulates osteoblast differentiation and inhibits osteoclast formation. *Journal of Bone and Mineral Research*, 2013; 28(7): 1599-610, PMID: 23408651.

7. Casson L, Howell L, Mathews LA, Ferrer M, Southall N, Guha R, Keller JM, Thomas C, Siskind LJ, Beverly LJ. Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. *PLoS One*. 2013, 8(1): e54525.

8. Ceresa, B.P. <u>Spatial Regulation of Epidermal Growth Factor Receptor Signaling by</u> <u>Endocytosis Int. J. Mol. Sci.</u>, 2013, 14(1), 72-87; doi:<u>10.3390/ijms14010072</u>

9. Cheng P-H, Lian S, Zhao R, Rao X-M, McMasters KM, Zhou HS. Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells. Virology Journal, 2013, 10(1):293. doi:10.1186/1743-422X-10-293. Sep 23.

10. Cheng P-H, Rao X-M, McMasters KM, Zhou HS. Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E. PLoS ONE, 2013, 8(2): e57340. doi:10.1371/journal.pone.0057340. Epub 2013 Feb 20.

11. Chung DH, Vastermark A, Camp JV, McAllister RC, Remold SK, Chu YK, Bruder C, Jonsson CB. (2013) *The murine model for Hantaan virus-induced lethal disease shows two distinct paths in viral evolutionary trajectory with and without ribavirin treatment.* J Virol, 2013. 87(20):10997-11007.

12. Dong DY, Wang B, Yin W, Ding XQ, Yu JJ, Kang YJ. Disturbance of copper homeostasis is a mechanism for homocysteine-induced vascular endothelial cell injury. *Plos One*, 2013, 8 (10): e76209.

13. Fu Z, Shrubsole MJ, Li G, Smalley WE, Hein DW, Cai Q, Ness RM, Zheng W: Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps. *Carcinogenesis*, 2013, 34:779-786. [PMCID: PMC3616674]

14. Gibson TM, Smedby KE, Skibola CF, Hein DW, Slager SL, De Sanjose S, Vajdic CM, Zhang Y, Chiu BC, Wang SS, Hjalgrim H, Nieters A, Bracci PM, Kricker A, Zheng T, Kolar C, Cerhan JR, Darabi H, Becker N, Conde L, Holford TR, Weisenberger DD, De Roos AJ, Butterbach K, Riby J, Cozen W, Benavente Y, Palmers C, Holly EA, Sampson JN, Rothman N, Armstrong BK, Morton LM: Smoking, variation in *N*-acetyltransferase 1 (*NAT1*) and 2 (*NAT2*), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. *Cancer Causes and Control*, 2013, 24:125-134. [PMCID: PMC3529854]

15. Gobejishvili L, Barve S, Breitkopf-Heinlein K, Li Y, Zhang J, <u>Avila D</u>, Dooley S, McClain, CJ. Rolipram Attenuates Bile Duct Ligation-Induced Liver Injury in Rats; A Potential Pathogenic Role of PDE4. J Pharmacol Exp Ther, 2013, Oct;347(1):80-90. Epub 2013 Jul 25. PMID: 23887098; PMCID:PMC3781411

16. Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N. Efficient single tobamovirus vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in *Nicotiana benthamiana* plants and utility of VRC01 in combination microbicides. *Antimicrobial Agents and Chemotherapy*, 2013, 57(5):2076-86 PMID: 23403432 PMCID in process.

17. Hamorsky KT, Kouokam JC, Bennett L, Baldauf KJ, Kajiura H, Fujiyama K, Matoba N. Rapid and Scalable Plant-based Production of a Cholera Toxin B Subunit Variant to Aid in Mass Vaccination against Cholera Outbreaks. <u>PLoS Neglected Tropical Diseases</u>, 2013 e2046.

18. Harrison BJ, Flight RM, Gomes C, Venkat G, Ellis, SR, Sankar U, Twiss JL, Rouchka, EC, Petruska JC. IB4-binding sensory neurons in the adult rat express a novel 3' UTR-extended isoform of CaMK4 that is associated with its localization to axons. *J Comp Neurol*, 2013, Jul 1. doi: 10.1002/cne.23398. [Epub ahead of print] PMID: 23817991.

19. He W, Kang YJ. Ischemia-induced copper loss and suppression of angiogenesis in the pathogenesis of myocardial infarction. *Cardiovas Toxicol*, 2013, 13:1-8.

20. Jiang X, **Skibba M**, Zhang C, Tan Y, Xin Y, Qu Y. 2013. The Roles of Fibroblast Growth Factors in the Testicular Development and Tumor. J. Diabetes Research 2013, 1-8.

21. Jones DZ, Ragin C, Kidd NC, Flores-Obando RE, Jackson M, McFarlane-Anderson N, Tulloch-Reid M, Kimbro KS, Kidd LR. The impact of genetic variants in inflammatory-related

genes on prostate cancer risk among men of African Descent: a case control study. Hered Cancer Clin Pract., 2013, 11(1):19

22. Kaiser JP, Arteel GE. The role of plasminogen activated inhibitor-1 in alcoholic liver disease. In: Recent advances in alcoholic liver diseases (Romani A, ed) Transworld Research Network, Kerala, India. 2013

23. Kang YJ. (2013) Regenerative Medicine Research: an open access translational medicine journal. Regenerative Medicine Research, 2013, 1:1 doi:10.1186/2050-490X-1-1

24. Kang, Y. J., Chapter 18, "Toxic responses of the heart and vascular system." In the "Casarett & Doull's TOXICOLOGY: The Basic Science of Poisons" edited by Curtis D. Klaassen, 8th edition, McGraw-Hill Companies, Inc., 2013, pp 799-838.

25. Kang YJ, Zheng LL. Rejuvenation: An integrated approach to regenerative medicine. <u>*Regen*</u> <u>*Med Res*</u>, 2013, 1(1):1-8.

26. Kausar H, Munagala R, Bansal S, Aqil F Vadhanam MV, Gupta RC. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets. *Cancer Letter*. 2013, 332: 35-45.

27. Kessans SA, Linhart MD, Matoba N, Mor TS. Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana. Plant Biotechnol J. 2013, 11(6)681-90.

28. Kidd LR, Rogers, EN, Yeyeodu ST, Jones, DZ, Kimbro KS. Contribution of toll-like receptor signaling pathways to breast tumorigenesis: Breast Cancer and Treatment Strategies. *Breast Cancer: Targets and Therapy.* 2013, 5:43-51

29. Kirpich IA, Feng W, Wang Y, Liu Y, Beier JI, Arteel GE, Falkner KC, Barve SS, McClain CJ.

Ethanol and Dietary Unsaturated Fat (Corn Oil/Linoleic Acid Enriched) Cause Intestinal Inflammation and Impaired Intestinal Barrier Defense in Mice Chronically Fed Alcohol. *Alcohol*, 2013; 47(3):257-64. PMCID: PMC3617059

30. Korrapati MC, Howell LH, Shaner BE, Megyesi JK, Siskind LJ, Schnellmann RG. Suramin: a potential therapy for diabetic nephropathy. *PLoS One*. 2013, 8(9):e73655

31. Kotsikorou E, Navas F 3rd, Roche MJ, Gilliam AF, Thomas BF, Seltzman HH, Kumar P, Song ZH, Hurst DP, Lynch DL, Reggio PH. The Importance of Hydrogen Bonding and Aromatic Stacking to the Affinity and Efficacy of Cannabinoid Receptor CB2 Antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528). J Med Chem, 2013, 56(17):pp6593-6612. PMID: 23855811

32. Kumar P, Song ZH. Identification of raloxifene as a novel CB2 inverse agonist. Biochem Biophys Res Commun, 2013, 435(1):pp76-81. PMID: 23611779

33. Kumar P, Kumar A, Song ZH (2013) Structure-activity relationships of fatty acid amide ligands in activating and desensitizing G protein-coupled receptor 119, Eur J Pharmacol, 2013 Oct 30. pii: S0014-2999(13)00805-4. doi: 10.1016/j.ejphar.2013.10.044. PMID: 24184668

34. Li QF, Ding XQ, Kang YJ. Copper promotion of angiogenesis in isolated rat aortic ring: Role of vascular endothelial growth factor. *J Nutri Biochem*, 2013, 25:44-49.

35. Luís FF, Neves L, Van Rite BD, Ramesh R, Resasco DE, Harrison RG. Targeting singlewalled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology, 2013 Sep 20; 24(37):5104 doi:10.1088/0957-4484/24/37/375104

36. Lukashevich IS. The search for animal models for Lassa fever vaccine development. <u>Expert</u> <u>Rev Vaccines</u>. 2013 Jan;12(1):71-86. doi: 10.1586/erv.12.139.

37. McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE. PharmGKB Very important pharmacogene (VIP) for N-acetyltransferase 2. Published online at <a href="https://www.pharmgkb.org/gene/PA18#tabview=tab3&subtab=32">https://www.pharmgkb.org/gene/PA18#tabview=tab3&subtab=32</a>.

38. Munagala R, Aqil F, Vadhanam MV, Gupta RC. MicroRNA 'signature' during estrogenmediated mammary carcinogenesis and its reversal by ellagic acid intervention. *Cancer Letters*, 2013, 339: 175-184.

39. Ngalame N, Micciche A, Feil M, States JC. Delayed temporal increase of hepatic Hsp70 in ApoE knockout mice after prenatal arsenic exposure. Toxicol Sci., 2013, 131: 225-233

40. Nixon B, Stefanidou M, Mesquita PM, Fakioglu E, Segarra T, Rohan L, Halford W, Palmer KE, Herold BC. Griffithsin prevents genital herpes in mice by preventing cell to cell spread. *Journal of Virology*, 2013, 87(11):6257-69. PMID: 23536670 PMCID in process

41. Palmer KE, Gleba Y (editors). *Plant Viral Vectors*. Current Topics in Microbiology and Immunology Vol. 375. Springer Verlag: Heidelberg, 194 pages. ISBN 978-3-642-40829-8, 2013

42. Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, Eeles R, Fernandez P, Giri VN, Gueye SM, Haiman CA, Henderson BE, Heyns CF, Hu JJ, Ingles SA, Isaacs W, Jalloh M, John EM, Kibel AS, Kidd LR, Layne P, Leach RJ, Neslund-Dudas C, Okobia MN, Ostrander EA, Park JY, Patrick AL, Phelan CM, Ragin C, Roberts RA, Rybicki BA, Stanford JL, Strom S, Thompson IM, Witte J, Xu J, Yeboah E, Hsing AW, Zeigler-Johnson CM. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer. 2013:560857.

43. Richard EM, Thiyagara T, Bunni MA, Basher F, Roddy PO, Siskind LJ, Nietert PJ, Nowling TK. Reducing FLI1 Levels in the MRL/lpr Lupus Mouse Model Impacts T Cell Function by Modulating Glycosphingolipid Metabolism. *PLoS One.*, 2013, 8(9):e75175

44. Rogers EN, Jones DZ, Kidd NC, Yeyeodu S, Brock G, Ragin C, Jackson M, McFarlane-Anderson N, Tulloch-Reid M, Sean Kimbro K, Kidd LR. Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent. Genes Immun., 2013, 14(6):347-55

45. Rush JS, Ceresa B.P. RAB7 and TSG101 are required for the constitutive recycling of unliganded EGFRs via distinct mechanisms. *Mol Cell Endocrinol.*, 2013, 381(1-2):188-197.

46. Schmidt RH, Jokinen JD, Massey VM, Falkner KC, Shi X, Yin X, Zhang X, Beier JI, Arteel GE. Olanzapine Activates Hepatic Mammalian Target Of Rapamycin (Mtor): New Mechanistic Insight Into Metabolic Dysregulation With Atypical Antipsychotic Drugs. *J Pharmacol Exp Ther.* 2013; 347(1):126-35. PMCID: PMC3781405

47. Sharma RJ, Aqil F, Jeyabalan J, Gupta RC, Singh IP. Quantitative Analysis of *Eugenia jambolana* (Willd. Ex O.Berg) for Its Major Anthocyanins by Densitometry. J. Planar Chromat., 2013, 26(4): 363–369.

48. Shukla SD, Pruett SB, Szabo G, Arteel GE. Binge ethanol and liver: new molecular developments. *Alcoholism: Clinical and Experimental Research*, 2013, 37:550-7

49. Siskind, LJ, Beverly, LJ. Breaking through the tunnel vision: toward a unified model for the role of sphingolipids in apoptosis. ASBMB Today. 2013, 13(9): 25-26

50. Song M, Schuschke DA, Zhou Z, Chen T, Shi X, Zhang J, Zhang X, Pierce WM Jr, Johnson WT, Vos MB, McClain CJ. <u>Modest fructose beverage intake causes liver injury and fat</u> <u>accumulation in marginal copper deficient rats</u>. *Obesity (Silver Spring)*. 2013 Aug;21(8):1669-75. doi: 10.1002/oby.20380. Epub 2013 May 31.

51. Sun XR, Cai JD, Fan X, Han PF, Xie YP, Chen JM, Xiao Y, Kang YJ. Decreases in electrocardiographic R-wave amplitude and QT interval predict myocardial ischemic infarction in Rhesus monkeys with left anterior descending artery ligation. *Plos One*, 2013, 8 (8): e71876.

52. Tretyakova I, Lukashevich IS, Glass P, Wang E, Weaver S, Pushko P. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. <u>Vaccine</u>, 2013, 31:1019-1025.

53. Vuyyuri, S B, Rinkinen, J, Worden, E, Shim, H, Lee, S, Davis, K R. Ascorbic acid and a cytostatic inhibitor of glycolysis synergistically induce apoptosis in non-small cell lung cancer cells. PLoS ONE, 2013, 8(6): e67081.

54. Wahlang B, Beier JI, Clair HB, Bellis-Jones HJ, Falkner KC, McClain CJ, Cave MC. Toxicant-Associated Steatohepatitis. *Toxicol Pathol.*, 2013; 41(2):343-60. Review.

55. Wahlang, B, Falkner, KC, Gregory, B, Ansert, D, Young, D, Conklin, DJ, McClain, CJ Bhatnagar, A, Cave, M. Polychlorinated Biphenyl 153 Is a Diet-dependent Obesogen Which Worsens Nonalcoholic Fatty Liver Disease In C57BL6/J Mice. J Nutr Biochem. 2013 Sep;24(9):1587-95. doi: 10.1016/j.jnutbio.2013.01.009. Epub 2013 Apr 22

56. Wang B, Dong DY, Kang YJ. Copper chaperone for superoxide dismutase-1 transfers copper to mitochondria but does not affect cytochrome c oxidase activity. *Exp Biol Med*, 2013, 238:1017-1023

57. Wecker L., Engberg ME, Philpot RM, Lambert CS, Kang CW, Antilla JC, Bickford PC, Hudson CE, Zesiewicz TA, Rowell, PP. Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia. *Neuropharm.* 2013, 73: 75-86, 2013.

58. Wei X, Shi X, Koo I, Kim S, Schmidt RH, Arteel GE, Watson WH, McClain C, Zhang X MetPP: a computational platform for comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. *Bioinformatics*, 2013, 29:1786-92.

59. Xu X, Shi F, Huang WL, Kang YJ. Metallothionein gene transfection reverses the phenotype of activated human hepatic stellate cells. *J Pharmacol Exp Ther*, 2013, 346:48-53.

60. Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW, Mitchell RA: Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. *J Immunol* 2013, 190(6):2984-2993.

61. Yeyeodu ST, Kidd LR, Oprea-Ilies GM, Burns BG, Vancleave TT, Shim JY, Kimbro KS. *IRAK4* and *TLR3* Sequence Variants may Alter Breast Cancer Risk among African-American Women. *Front Immunol.* 2013, 4:338.

62. Zapata JC, Carrion R Jr, Patterson JL, Crasta O, Zhang Y, Mani S, Jett M, Poonia B, Djavani M, David M, White DM, Lukashevich IS, Salvato MS. Transcriptome Analysis of Human Peripheral Blood Mononuclear Cells Exposed to Lassa Virus and to the Reassortant ML29, a Vaccine Candidate. <u>PLoS Negl Trop Dis</u>, 2013, 7(9): e2406; doi:101371/journal.pntd.0002406.

63. Zapata JC, Poonia B, Bryant J, Davis H, Ateh E, George L, Crasta O, Zhang Y, Slezak T, Jaing C, Pauza CD, Goicochea M, Moshkoff D, Lukashevich IS. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. <u>Virology J</u>, 2013, Feb 12;10(1):52

64. Zhang C, Zhang L, Chen S, Feng B, Lu X, Bai Y, Liang G, Tan Y, Shao M, **Skibba M**, Jin L, Li X, Chakrabarti S, Cai L. The prevention of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably mediated by the suppression of oxidative stress and damage. PLoS One. 2013 Dec 9;8(12):e82287.

65. Zuo X, Dong DY, Sun M, Xie HQ, Kang YJ. Homocysteine restricts copper availability leading to suppression of cytochrome c oxidase activity in phenylephrine-treated cardiomyocytes. *Plos One*, 2013, 8 (6): e67549.

# PHARMACOLOGY & TOXICOLOGY ABSTRACTS Faculty with Primary Appointments and Students

#### Arteel, Gavin:

National/International

1. Mohammad M, Avila D, Zhang J, Barve S, Arteel G, McClain C, Joshi-Barve S (2013) Acrolein Cytotoxicity in Hepatocytes Involves Endoplasmic Reticulum Stress, Mitochondrial Dysfunction, and Oxidative Stress. *The Toxicologist* 132:139.

2. Schmidt RS, Massey VL, Jokinen J, Falkner KC, Beier JI, Arteel GE (2013) Olanzapineinduced liver injury: direct metabolic effects on liver and exacerbation by high-fat diet. *Hepatology* 58:544A.

3. Massey VL, Schmidt RH, Tan M, Watson WH, Arteel GE (2013) The prebiotic oligofructose protects against enhanced liver injury caused by arsenic in a model of NASH. *Hepatology* 58:559A.

# Local/Regional

4. Massey V, Schmidt R, Tin M, Watson W and Arteel G (2013) The prebiotic oligofructose protects against enhanced liver injury caused by arsenic in a model of non-alcoholic fatty liver disease. Ohio Valley Society of Toxicology annual meeting. (*selected for a platform presentation; 1st place student award*).

5. Poole L, Jokinen J, Massey V, Beier J, and Arteel G (2013) Sinusoidal endothelial cell-derived extracellular matrix regulates basal and stimulated macrophage activation. Ohio Valley Society of Toxicology annual meeting

6. Ramakrishnan VM, Burchell PO, Beier JI, Dale JR, Arteel GE, Hoying JB, Williams SK, and Boyd NL (2013) Adipose Stromal Vascular Fraction-Derived Vasculature Supports Implantation of Parenchymal Hepatocytes. Research!Louisville. *(2nd place Medical Student Poster Award)*.

7. Warner NL, Beier JI, Jokinen JD, Holz GE, Arteel GE (2013) Modification of epithelial monolayer integrity increases apical infectivity to lymocytic choriomeningtitis virus (LCMV) in Caco-2 cells. Research!Louisville.

8. Holz G, Beier J, Jokinen J, Warner N, Arteel G, and Lukashevich I (2013) Design of tissue culture model to study interactions between macrophages and hepatocytes in arenavirus-induced liver pathology. Research!Louisville.

9. Massey V, Schmidt R, Tin M, Watson W and Arteel G (2013) The prebiotic oligofructose protects against enhanced liver injury caused by arsenic in a model of non-alcoholic fatty liver disease. Research!Louisville.

10. Poole L, Jokinen J, Massey V, Beier J, and Arteel G (2013) Sinusoidal endothelial cellderived extracellular matrix regulates basal and stimulated macrophage activation. Research!Louisville. 11. Arteel G, Schmidt R, Massey V, Jokinen J, Falkner KC, Shi X, Yin X, Zhang X, and Beier J (2013) Olanazapine-induced liver injury: direct metabolic effects on liver and exacerbation by high-fat diet. Research!Louisville. *(Ist place Faculty Basic Science Award).* 

12. Watson W, Shi X, Vaughn A, Schmidt R, McClain C, Arteel G, and Zhang X (2013) Metabolomic analysis of the effects of chronic arsenic exposure in a mouse model of diet-induced fatty liver disease. Research!Louisville.

#### Arteel, Juliane Beier:

# National/International

1. Warner NL, Kirpich IA, Mohammad MK, Falkner KC, Cave M, McClain CJ and **Beier JI** (2013) Vinyl Chloride And/Or Its Metabolites Induce Hepatic Necro-Inflammation In Mice And In Human Subjects With Chronic Low-Level Exposures. *Hepatology* 58:949A.

2. Kirpich IA, Liu H, Falkner KC, **Beier JI**, Joshi-Barve S, Ramsden C, McClain CJ, Cave M (2013) Occupational Vinyl Chloride Exposures Increase Plasma Lipid Peroxidation Products (Including 13-Hode) Capable Of Causing Mitochondiral Dysfunction And Endoplasmic Reticulum Stress? Novel Modes Of Action For Toxicant Associated Steatohepatitis (TASH). *Hepatology* 58:952A.

3. Wahlang B, Song M, **Beier JI**, Al-Eryani L, Clair HB, Guardiola JJ, Falkner KC, Prough RA, Cave M (2013) Aroclor 1260 Exposure Worsens Hepatic And Systemic Inflammation In An Animal Model Of Diet-Induced Obesity And Nonalcoholic Fatty Liver Disease. *Hepatology* 58:533A.

4. Schmidt RH, Massey VM, Jokinen JJ, Falkner KC, **Beier JI**, Arteel GE (2013) Olanzapineinduced liver injury: direct metabolic effects on liver and exacerbation by high-fat diet. *Hepatology* 58:544A.

# Local/Regional

1. Anders LC, Douglas AN, Warner NL, Kirpich IA, Mohammad MK, Falkner KC, Cave M, McClain CJ and **Beier JI** (2013) Vinyl Chloride And/Or Its Metabolites Induce Hepatic Necro-Inflammation In Mice And In Human Subjects With Chronic Low-Level Exposures. OVSOT annual meeting, Louisville, KY.

2. Wahlang B, Song M, **Beier JI**, Al-Eryani L, Clair HB, Guardiola JJ, Falkner KC, Prough RA, Cave M (2013) Aroclor 1260 Exposure Worsens Hepatic And Systemic Inflammation In An Animal Model Of Diet-Induced Obesity And Nonalcoholic Fatty Liver Disease. OVSOT annual meeting, Louisville, KY. (*Best graduate student presentation award*).

3. Poole LG, Jokinen JD, Massey VL, **Beier JI**, and Arteel GE (2013) Sinusoidal endothelial cellderived extracellular matrix regulates basal and stimulated macrophage activation. OVSOT annual meeting, Louisville, KY.

4. Anders LC, Douglas AN, Warner NL, Kirpich IA, Mohammad MK, Falkner KC, Cave M, McClain CJ and **Beier JI** (2013) Vinyl Chloride And/Or Its Metabolites Induce Hepatic Necro-Inflammation In Mice And In Human Subjects With Chronic Low-Level Exposures. Research!Louisville.

5. Whang PS, **Beier JI**, Jokinen JD, Martin AM, Warner NL, Arteel GE and Lukashevich IS (2013). A Novel Mechanism of Arenavirus-induced Liver Pathology. Research!Louisville.

6. Holz GE, **Beier JI**, Jokinen JD, Warner NL, Arteel GE, Lukashevich IS (2013) Design of tissue culture model to study interaction between macrophages and hepatocytes in Arenavirus-induced liver pathology. Research!Louisville.

7. Warner NL, **Beier JI**, Jokinen JD, Holz GE, Arteel GE, Lukashevich IS (2013) Modification of epithelial cell monolayer integrity increases apical infectivity to lymphocytic choriomeningitis virus (LCMV) in Caco-2 cells. Research!Louisville.

8. Poole LG, Jokinen JD, Massey VL, **Beier JI**, and Arteel GE (2013) Sinusoidal endothelial cellderived extracellular matrix regulates basal and stimulated macrophage activation. Research!Louisville.

9. Schmidt RH, Massey VM, Jokinen JJ, Falkner KC, **Beier JI**, Arteel GE (2013) Olanzapineinduced liver injury: direct metabolic effects on liver and exacerbation by high-fat diet. Research!Louisville. (*Most Promising Basic Science Faculty Award*).

10. Kirpich IA, Liu H, Falkner KC, **Beier JI**, Joshi-Barve S, Ramsden C, McClain CJ, Cave M (2013). Occupational Vinyl Chloride Exposures Increase Plasma Lipid Peroxidation Products (Including 13-Hode) Capable Of Causing Mitochondiral Dysfunction And Endoplasmic Reticulum Stress? Novel Modes Of Action For Toxicant Associated Steatohepatitis (TASH). Research!Louisville.

11. Ramakrishnan VM, Burchell PO, **Beier JI**, Dale JR, Arteel GE, Hoying JB, Williams SK, and Boyd NL (2013) Adipose Stromal Vascular Fraction-Derived Vasculature Supports Implantation of Parenchymal Hepatocytes. Research!Louisville. (*2nd place Medical Student Poster Award*).

# **Benz, Frederick:**

1. Jian Cai, Harrell Hurst, Donald Nerland, Daniel Wilkey, Michael Merchant, FW Benz. Identification Of Rat Liver Protein Targets Of Acrylonitrile In Vivo Using Two-Dimensional Liquid Chromatography And Mass Spectrometry. Research! Louisville, September 24-27, 2013, Louisville, KY

#### Ceresa, Brian:

1. Peterson, J.L. and **Ceresa, B.P**., Analysis of EGFR ligand found in human tears reveals differences in corneal epithelial wound healing and ligand induced EGFR signaling, American Society for Cell Biology, 2013.

2. Rush, J.S. and **Ceresa**, **B.P**., c-Cbl as a therapeutic target for Enhanced Human Corneal Epithelial Wound Healing, American Society for Cell Biology, 2013.

3. Parks, E.E. and **Ceresa, B.P**., EGFR Signaling from the Plasma Membrane, American Society for Cell Biology, 2013.

4. Peterson, J.L. and **Ceresa, B.P**., Analysis of EGFR ligand found in human tears reveals differences in corneal epithelial wound healing and ligand induced EGFR signaling, Research!Louisville, 2013.

5. Rush, J.S. and **Ceresa**, **B.P**., c-Cbl as a therapeutic target for Enhanced Human Corneal Epithelial Wound Healing, Research!Louisville, 2013.

6. Parks, E.E. and **Ceresa, B.P**., EGFR Signaling from the Plasma Membrane, Research!Louisville, 2013.

7. Jackson, N. and **Ceresa, B.P**., Endogenous EGFR Ligands as Mediators of Apoptosis in Metastatic Breast Cells. Research!Louisville, 2013

8. Sangoi, T. and Ceresa, B.P., Endocytic Trafficking of Mutant Epidermal Growth Factor Receptors in Lung Cancer Research!Louisville, 2013

9. Peterson, J.L. and **Ceresa, B.P**. Analysis of EGFR ligands found in human tears reveals differences in corneal epithelial wound healing and ligand induced EGFR signaling 75th Harden Conference - Receptor Tyrosine Kinase Structure and Function in Mammalian Health and Disease, September 2013

10. **Ceresa, B.P.,** Peterson J.L., Pharmacological Analysis of Epidermal Growth Factor Receptor Ligands on Corneal Epithelial Cells, May 2013: Association for Research in Vision and Ophthalmology

# Gupta, Ramesh:

1. Munagala R, Aqil F, Taylor DD & **Gupta R**. Tumor-derived circulatory exosomal miRNAs as biomarkers of recurrent lung tumors. *Proc. Am. Cancer Res.* 53: 1947, 2013.

2. Jeyabalan J, Aqil F, Munagala R & **Gupta RC**. Chemopreventive and therapeutic activity of high anthocyanin-content blueberry against estrogen-mediated breast cancer. *Proc. Am. Cancer Res.* 53: 3705, 2013.

3. Vadhanam MV, **Gupta RC** & McNally LR. Targeting IGF-1R for Inhibition of Pancreatic Cancer Metastasis by Pomegranate Fraction. *Proc. Am. Cancer Res.* 53: 3680, 2013.

4. Aqil F, Munagala R, Kausar, H, Jeyabalan J. & **Gupta RC**. Enhanced activity of chemotherapeutic drugs by blueberry anthocyanidins and withaferin A against human lung cancer cells. *Proc. Am. Cancer Res.* 53: 3678, 2013.

5. **Gupta RC**, Aqil F, Kausar H, Jeyabalan J, Vadhanam MV & Munagala R. Therapeutic Potential of Blueberry Anthos ('Color' Therapy). Berry Health Benefits Symposium, Charlotte, NC, June 18-20, 2013.

### Hein, David:

1.Hein, D.W. and Kidd, L.R.: First year cohort results for the NCI R25 University of Louisville Cancer Education Program. Proceedings of the annual Experimental Biology meetings, Boston, Massachusetts, April 2013.

2. Sanford, C.E., Carlisle, S.M., Doll, M.A., States, J. S., and Hein, D.W.: The effect of arylamine N-acetyltransferase 1 specific inhibitor and curcumin or resveratrol on the proliferation of a breast cancer cell line. James Graham Brown Cancer Center Summer Internship Program, August, 2013.

3.Carlisle, S.M., Doll, M.A., States, J. S., and Hein, D.W.: The effect of arylamine Nacetyltransferase 1 specific inhibitor and curcumin or resveratrol on the proliferation of a breast cancer cell lines. Proceedings of the annul meeting of the Ohio Valley Society of Toxicology, Louisville, Kentucky, September, 2013.

4. Stepp, M.W., Doll, M.A., Sanders, M.A., and Hein, D.W.: Fisher 344 rat strains congenic at arylamine N-acetyltransferase differ in breast tumorigenesis induced by N-methynitrosourea. Proceedings of the annual meeting of the Ohio Valley Society of Toxicology, Louisville, Kentucky, September, 2013.

5. Bodduluri, S., Doll, M.A., Gonzalez, R.A.S., and Hein, D.W.: Acetylator genotype-dependent N-acetylation of isoniazid in human hepatocytes in situ. Proceedings of Research!Louisville Abstract UCE-102, Louisville, Kentucky, September, 2013.

6. Carlisle, S.M., Doll, M.A., States, J. S., and Hein, D.W.: The effect of arylamine Nacetyltransferase 1 specific inhibitor and curcumin or resveratrol on the proliferation of a breast cancer cell lines. Proceedings of Research!Louisville Abstract GRM-6, Louisville, Kentucky, September, 2013.

7. Stepp, M.W., Doll, M.A., Sanders, M.A., and Hein, D.W.: Fisher 344 rat strains congenic at arylamine N-acetyltransferase differ in breast tumorigenesis induced by N-methynitrosourea. Proceedings of Research!Louisville Abstract GRM-37, Louisville, Kentucky, September, 2013.

8. Doll, M.A., Gonzalez, R.A.S., and Hein, D.W.: Acetylator genotype-dependent N-acetylation of isoniazid in human hepatocytes in situ. Proceedings of the Sixth International Workshop on Arylamine N-acetyltransferases, Toronto, Canada, October 2013.

9. Carlisle, S.M., Doll, M.A., States, J. S., and Hein, D.W.: The effect of arylamine N-acetyltransferase 1 specific inhibitor and curcumin or resveratrol on the proliferation of a breast cancer cell lines. Proceedings of the Sixth International Workshop on Arylamine N-acetyltransferases, Toronto, Canada, October 2013.

10. Hein, D.W.: NAT2 polymorphisms and disease risk: Implications of genetic heterogeneity in the slow acetylator phenotype. Proceedings of the Sixth International Workshop on Arylamine N-acetyltransferases, Toronto, Canada, October 2013.

11. Stepp, M.W., Doll, M.A., Sanders, M.A., and Hein, D.W.: Rapid arylamine *N*-acetyltransferase congenic rats show increase of chemically induced breast tumors by 1-methyl-1-nitrosourea. Proceedings of the Sixth International Workshop on Arylamine N-acetyltransferases, Toronto, Canada, October 2013.

12. Carlisle, S.M., Doll, M.A., States, J. S., and Hein, D.W.: The effect of arylamine N-acetyltransferase 1 specific inhibitor and curcumin or resveratrol on the proliferation of a breast cancer cell lines. Proceedings of the 12<sup>th</sup> Annual James Graham Brown Cancer Center Retreat, Abstract #15, Louisville, Kentucky, October, 2013.

13. Doll, M.A., Gonzalez, R.A.S., and Hein, D.W.: Acetylator genotype-dependent N-acetylation of isoniazid in human hepatocytes in situ. Proceedings of the 12<sup>th</sup> Annual James Graham Brown Cancer Center Retreat, Abstract #22, Louisville, Kentucky, October, 2013.

14. Sanford, C.E., Carlisle, S.M., Doll, M.A., States, J. S., and Hein, D.W.: The effect of arylamine N-acetyltransferase 1 specific inhibitor and curcumin or resveratrol on the proliferation of a breast cancer cell line. Proceedings of the 12<sup>th</sup> Annual James Graham Brown Cancer Center Retreat, Abstract #23, Louisville, Kentucky, October, 2013.

15. Stepp, M.W., Doll, M.A., Sanders, M.A., and Hein, D.W.: Fisher 344 rat strains congenic at arylamine N-acetyltransferase differ in breast tumorigenesis induced by 1-methyl-1-nitrosourea. Proceedings of the 12<sup>th</sup> Annual James Graham Brown Cancer Center Retreat, Abstract #101, Louisville, Kentucky, October, 2013.

#### Hurst, Harrell:

1. Jian Cai, Harrell Hurst, Donald Nerland, Daniel Wilkey, Michael Merchant, FW Benz. Identification Of Rat Liver Protein Targets Of Acrylonitrile In Vivo Using Two-Dimensional Liquid Chromatography And Mass Spectrometry. Research! Louisville, September 24-27, 2013, Louisville, KY

# Kidd, LaCreis:

#### Local Abstracts

1. Jones D.Z., Linder J., Avila D.V., Gobejishvili L., Barker D., Schmidt L., Hobbing K., Clark G., and **Kidd L.R.** TGF-beta Signaling in prostate cancer cell lines derived from Euorpean- and African-American men. Research Louisville!, Louisville, Kentucky, September 24, 2013.

2. Linder J., Jones D.Z., Avila D.V., Gobejishvili L., Barker D., Schmidt L., Hobbing K., Clark G., and **Kidd L.R.** microRNA-885-5p and its role in the TGF-beta pathway using prostate cancer cell lines derived from Euorpean- and African-American men. Research Louisville!, Louisville, Kentucky, September 24, 2013.

3. Jones D.Z., Linder J., Avila D.V., Gobejishvili L., Barker D., Schmidt L., Hobbing K., Clark G., and **Kidd L.R.** TGF-beta Signaling in prostate cancer cell lines derived from Euorpean- and African-American men. James Graham Brown Cancer Center Retreat, Louisville, Kentucky, October 25, 2013.

#### National Abstracts

1. Jones D.Z., Linder J., Avila D.V., Gobejishvili L., Barker D., Schmidt L., Hobbing K., Clark G., and **Kidd L.R.** micro-RNA 885-5p and its role in the TGF-β pathway using prostate cancer cell lines derived from European- and African-American men. AACR Annual Meeting, San Diego, CA, April, 2014.

2. Jones D.Z., Anene, D., Aloway, A., Anene, P., Avila, D., Gobejishvili L., Barve, S., McNally, L., and **Kidd L.R.** Reduced Expression of miR-342-3p in stage I, III, and IV Prostate Cancer. AACR Annual Meeting, Washington, D.C., April, 2013.

#### International Abstracts

1. Kimbro, K.S., Cortez, L., Yeyeodu, S.T., **Kidd, L.R.**, Oprea, G.M., Burns, B.G., VanCleave, T.T., Shim, J.Y., Rogers, E.N. *IRAK4 modulates growth and migration in breast cancer cells*. 17th European Cancer Congress 2013, Amsterdam, Netherlands. September 30, 2013.

#### Lukashevich, Igor:

1. Lukashevich, I. S., Bredenbeek, P. Recombinant YF17D-Based Vaccine Against Lassa Fever. BIT's 5th World Congress of Vaccine, Hangzhou China, March 18-20, 2013, Program and Abstracts, p. 294.

2. Zapata, J., M.S. Salvato, **I.S. Lukashevich.** Safety and Genetic Stability of the ML29 Reassortant Vaccine for Lassa Fever as Revealed by Transcriptome Profiling of Human PBMC and by Deep Sequencing of Vaccine Sub-Population. Keystone Symposia on Molecular and Cellular Biology, Advancing Vaccines in the Genomics Era. Oct 31- Nov 4, 2013, Windsor Barra Hotel, Rio de Janeiro, Brazil. Program and Abstracts, p.58.

#### Matoba, Nobuyuki:

1. Baldauf K\*, Kouokam JC, Jala VR, Bodduluri H, **Matoba N**. "A Plant-Produced Cholera Toxin B Subunit Prevents Acute Colitis in a Mouse Model" 2013 International Congress of Mucosal Immunology, Vancouver, Canada, July 2013.

2. Hamorsky K, Baldauf K, **Matoba N\***. "Large-scale production of recombinant proteins in plants enabling mucosal delivery of biotherapeutics based on nanotechnology. KY Nanotech Symposium, Louisville, KY, August 2013.

3. Baldauf K\*, Kouokam JC, Bodduluri H, **Matoba N**. "A Plant-Produced Cholera Toxin B Subunit Prevents Acute Colitis in a Mouse Model" Research!Louisville, Louisville, KY, September 2013.

4. Hamorsky KT\*, Husk A, Morris MK, Hanson C, Hume S, Dubuisson J, **Matoba N**. "Engineering, characterization and anti-HIV/HCV activity of Avaren-Fc, an oligomannosespecific lectin-fuman IgG1 Fc chimera" Brown Cancer Center Retreat, Louisville, KY, October 2013.

5. Husk A\*, Hamorsky KT, **Matoba N**. "Plant-based production and characterization of a novel bispecific HIV microbicide" Brown Cancer Center Retreat, Louisville, KY, October 2013.

6. Zahin M\*, Ghim S, Joh J, Hume S, Miller MC, Mason H, **Matoba N**, Jenson AB. "Plant based recombinant vaccine: Purification of HPV-16 L1 protein from tobacco leaves" Brown Cancer Center Retreat, Louisville, KY, October 2013.

7. Kouokam JC\*, Husk A, Baldauf K, Hamorsky KT, **Matoba N**. "An Oligomannose-specific Lectin-Fc Chimera with Anti-HIV/HCV Activity Exhibits Excellent in vitro Safety Profiles" Brown Cancer Center Retreat, Louisville, KY, October 2013.

8. Grooms-Williams T\*, Hamorsky K, Kouokam J, Morris MK, Husk A, Baldauf K, Hanson C, **Matoba N**. "Toxicological Analysis of Avaren-Fc: A potential HIV vaginal microbicide" Brown Cancer Center Retreat, Louisville, KY, October 2013.

9. Baldauf K\*, Kouokam JC, Bodduluri H, **Matoba N**. "A Plant-Produced Cholera Toxin B Subunit Prevents Acute Colitis in a Mouse Model" Brown Cancer Center Retreat, Louisville, KY, October 2013.

10. Fuqua J\*, Augenstein A, Riedell S, Lasnik AB, Walker J, Hamorsky K, **Matoba N**, Palmer KE. "Next-generation HPV Prophylactic Vaccines: Optimizing Construct Design and Evaluating Mucosal Immunization Routes" Brown Cancer Center Retreat, Louisville, KY, October 2013.

# Nerland, Donald:

1. J. Cai, H.E. Hurst, D.E. Nerland, D.W. Wilkey, M.L. Merchant, and F.W. Benz. Identification of rat liver protein targets of acrylonitrile *in vivo* using two-dimensional liquid chromatography and mass spectrometry. Research!Louisville 2013, Louisville, KY, September 24-27, 2013.

# Palmer, Kenneth:

1. Augenstein A, Fuqua J, Riedell S, Lasnik AB, Walker J, Hamorsky K, Matoba N, **Palmer KE** Preclinical evaluation of next-generation HPV prophylactic vaccines. Midwest Student Biomedical Research Forum, Omaha, Nebraska, February 2013. *Ms. Abbe Augenstein, UofL MD student, class of 2016, won the second place prize for this presentation at the Midwest Student Biomedical Research Forum, after winning the Research!Louisville MD summer research student first prize.* 

2. Férir G, **Palmer KE**, Schols D (2013) Griffithsin, in combination with all antiretroviral drugs, potently inhibits HIV cellular transmission and destruction of target CD4 T cells. *Proceedings of the 2013 Conference on Retroviruses and Opportunistic Infections*. Atlanta, GA, March 2013.

3. Fuqua J, Augenstein A, Riedell S, Lasnik AB, Walker J, Hamorsky K, Matoba N, **Palmer KE** (2013) Next-generation HPV Prophylactic Vaccines: Optimizing Construct Design and

Evaluating mucosal immunization routes. International Mucosal Immunology Conference, Vancouver BC, July 2013.

4. Barton C, **Palmer KE** (2013) Pharmacokinetic profile of the antiviral lectin Griffithsin. *Research!Louisville* September 2013.

5. Fuqua J, Augenstein A, Riedell S, Lasnik AB, Walker J, Hamorsky K, Matoba N, **Palmer KE** (2013) Next-generation HPV Prophylactic Vaccines: Optimizing Construct Design and Evaluating mucosal immunization routes. Proceedings of the James Graham Brown Cancer Center Retreat, October 2013. *Dr. Joshua Fuqua, postdoctoral trainee in my laboratory, won the second place award in the postdoctoral trainee division for this presentation.* 

# Sankar, Uma:

1. Pritchard Z, Waddell S, Voor M and Sankar U. Improving Bone by Inhibition of CaMKK2: Analysis of Bone Strength and Architecture. Research! Louisville, September 2013, Louisville, KY

2. Pritchard Z, Cary, R, Novack D, Voor M and Sankar U. CaMKK2 Inhibition as a Novel Bone Anabolic Strategy in the Prevention of Post-Menopausal and Therapy-Induced Osteoporosis 35<sup>th</sup> Annual Meeting of the American Society for Bone and Mineral Research, October 4-7, 2013, Blatimore, MD. *Was selected to be presented as a Plenary Poster on October 4 and 5, and graduate student Zack Pritchard won a Young Investigator Travel Award for the meeting.* 

3. Wilkerson DC, Cates J, Thomas L, Rachel C and Sankar U. "Regulation of the Mitochondrial Fission GTPase Drp1 by the Sulfhydryl Oxidase GFER". 11<sup>th</sup> Annual Brown Cancer Center Retreat, October 25, 2013, The Olmstead, Louisville, KY.

# Siskind, Leah:

National/International

# Prior to University of Louisville:

1. Beverly LJ, Casson L, Metelli A, Howell L, and <u>Siskind LJ.</u> (2013) Targeting glycosphingolipid metabolism for the treatment of human leukemia. Poster presentation. Cancer Metabolism, Keystone Symposia, February 2013, Keystone, CO.

#### At University of Louisville:

1. Stathem M, Scherzer M, Casson L, Beverly LJ, and Siskind LJ. (2013) The role of sphingolipids in leukemia progression and treatment. Poster Presentation, *Mechanisms and Models in Cancer*. August 2013, Salk Institute, CA.

2. Scherzer M, Stathem M, Roddy P, Siskind LJ, and Beverly LJ. (2013) An unbiased approach to assess the role of sphingolipid metabolism in cancer biology. Poster Presentation, *Mechanisms and Models in Cancer*. August 2013, Salk Institute, CA.

3. Stathem M, Casson L, Beverly LJ, and Siskind LJ (2013) Glycosphingolipids as a target for the treatment of leukemia. Poster presentation. September 2013, *The International Ceramide Conference*. Long Island, NY.

4. Marimuthu S, Korrapati M, Howell L, Schnellmann R, and Siskind LJ. (2013) The role of glycosphingolipids in diabetic nephropathy. Poster presentation. September 2013, *The International Ceramide Conference*. Long Island, NY.

5. Marimuthu S, Korrapati MC, Blakely J, Wills L, Howell LH, Schnellmann RG, and Siskind LJ. (2013) The role of glycosphingolipids in mesangial cell hypertrophy and proximal tubule mitochondrial dysfunction during diabetic nephropathy. Poster Presentation SA-PO298, *American Society of Nephrology, Kidney week 2013, Atlanta, GA (Nov 5-10).* 

6. Siskind LJ, Korrapati MC, Whitaker R, Megyesi J, Schnellmann RG. (2013) Therapeutic Potential of Suramin in Diabetic Nephropathy. Poster Presentation SA-PO297, *American Society of Nephrology, Kidney week 2013*, Atlanta, GA (Nov 5-10).

7. Richards EM, Amani Z, Zhang J, Mather A, Siskind LJ, and Nowling TK. (2013) Reducing Fli1 levels in the MRL/lpr lupus prone mouse model impacts T cell activation and cytokine production. Poster, The American Association of Immunologists, Annual Meeting.

Local/Regional

Prior to University of Louisville

1. Beverly LJ, Casson L, Metelli A, Howell L, and Siskind LJ (2013) Tumor cell glycosphingolipid metabolism as a target for the treatment of cancers. *Institute of molecular drug design and diversity*. March 2013, Poster presentation.

At University of Louisville:

1. Casson L, Stathem M, Scherzer M, Siskind LJ and Beverly LJ (2013) Tumor cell glycosphingolipid metabolism as a target for the treatment of cancers. September 2013, Talk, *Midwest Blood Club*. Cinn, OH.

2. Stathem M, Casson L, Beverly LJ, and Siskind LJ. (2013) Tumor cell glycosphingolipid metabolism as a target for the treatment of cancers. September 2013, Poster Presentation, *Research!Louisville*, Louisville, KY.

3. Marimuthu S, Korrapati MC, Blakely J, Wills L, Howell LH, Schnellmann RG, and Siskind LJ. (2013) The role of glycosphingolipids in diabetic nephropathy. September 2013, Poster Presentation, *Research!Louisville*, Louisville, KY.

4. Sundaram K, Mather D, and Siskind LJ. (2013) Neutral ceramidase knockout protects cells from necrosis. September 2013, Poster Presentation, *Research!Louisville*, Louisville, KY.

5. Stathem M, Casson L, Beverly LJ, and Siskind LJ. (2013) Tumor cell glycosphingolipid metabolism as a target for the treatment of cancers. October 2013, Poster Presentation, *James Graham Brown Cancer Center Annual Retreat*, Louisville, KY.

6. Stathem M, Casson L, Beverly LJ, and Siskind LJ. (2013) Tumor cell glycosphingolipid metabolism as a target for the treatment of leukemia. Poster Presentation, *48<sup>th</sup> Annual Southeastern Regional Lipid Conference (SERLC)*, NOVEMBER 13-15, 2013, Cashiers, NC.

7. Marimuthu S, Korrapati MC, Blakely J, Wills L, Howell LH, Schnellmann RG, and Siskind LJ. (2013) The role of glycosphingolipids in diabetic nephropathy. Talk, *48<sup>th</sup> Annual Southeastern Regional Lipid Conference (SERLC)*, NOVEMBER 13-15, 2013, Cashiers, NC.

8. Sundaram K, Mather D, and Siskind LJ. (2013) Neutral ceramidase knockout protects cells from necrosis. Talk, *48<sup>th</sup> Annual Southeastern Regional Lipid Conference (SERLC)*, NOVEMBER 13-15, 2013, Cashiers, NC.

# Song, Zhao-Hui:

1. **Song ZH**, Kumar A, He, F. Molecular Chaperones in Cannabinoid Receptor Signaling, BIT's 6th Annual Protein and Peptide Conference, Suzhou, China, March 2013

2. **Song ZH**. Cannabinoid Receptors as Therapeutic Target. BIT's 6th Annual Protein and Peptide Conference, Suzhou, China, March 2013

3. Kumar P, **Song ZH.** Identification of raloxifene as a novel CB2 inverse agonist. International Cannabinoid Research Society Conference, Vancouver, Canada, June, 2013.

# States, J. Christopher:

1. L Al-Eryani, B Wahlang, KC Falkner, HB Clair, JJ Guardiola, RA Prough, JC States, M Cave. Identification of Xenobiotic Receptor Agonists which could contribute to Nonalcoholic Fatty Liver Disease. Research!Louisville, University of Louisville, Louisville, KY, September 25-29, 2013.

2. SM Carlisle, MA Doll, JC States, DW Hein. The Effect of a Human Arylamine N-Acetyltransferase 1 Specific Inhibitor and Curcumin or Resveratrol on the Proliferation of Breast Cancer Cell Lines. Research!Louisville, University of Louisville, Louisville, KY, September 25-29, 2013.

3. B Wahlang, M Song, JI Beier, LA Al-Eryani, HB Clair, KC Falkner, RA Prough, JC States, M Cave . Aroclor 1260 Exposure Worsens Hepatic and Systemic Inflammation in an Animal Model of Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease. Research!Louisville, University of Louisville, Louisville, KY, September 25-29, 2013.

4. NA Klimchak, BC Sils, JO Trent, JC States. Compounds Targeting the Anaphase Promoting Complex Inhibit Lung Cancer Cell Growth. Research!Louisville, University of Louisville, Louisville, KY, September 25-29, 2013.

5. D Saforo, B Sils, JC States. Candidate drugs binding the Anaphase Promoting Complex: A novel target for anticancer therapy. Research!Louisville, University of Louisville, Louisville, KY, September 25-29, 2013.

6. L Al-Eryani, B Wahlang, KC Falkner, HB Clair, JJ Guardiola, RA Prough, JC States, M Cave. Identification of Xenobiotic Receptor Agonists which could contribute to Nonalcoholic

Fatty Liver Disease. Ohio Valley Society of Toxicology, University of Louisville, Lousiville, KY, September 24, 2013.

7. B Wahlang, M Song, JI Beier, LA Al-Eryani, HB Clair, KC Falkner, RA Prough, JC States, M Cave . Aroclor 1260 Exposure Worsens Hepatic and Systemic Inflammation in an Animal Model of Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease. Ohio Valley Society of Toxicology, University of Louisville, Louisville, KY, September 24, 2013.

8. NA Klimchak, BC Sils, JO Trent, JC States. Compounds Targeting the Anaphase Promoting Complex Inhibit Lung Cancer Cell Growth. Ohio Valley Society of Toxicology, University of Louisville, Louisville, KY, September 24, 2013.

9. D Saforo, B Sils, JC States, Candidate drugs binding the Anaphase Promoting Complex: A novel target for anti-cancer therapy. Brown Cancer Center Retreat, October 25, 2013

10. NA Klimchak, BC Sils, JO Trent, JC States, Compounds Targeting the Anaphase Promoting Complex Inhibit Lung Cancer Cell Growth. Brown Cancer Center Retreat, October 25, 2013

11. D Saforo, B Sils, JC States, Candidate drugs binding the Anaphase Promoting Complex: A novel target for anti-cancer therapy. Society of Toxicology, Phoenix, AZ March 10-14, 2013

# **ACTIVE GRANTS/CONTRACTS & OTHER RESEARCH ACTIVITIES**

#### **Faculty with Primary Appointments**

Agency/	Title	Role	PI	Project	Budget
Number				Period	Award
Arteel, Gavin					
NIH	UofL Environmental Health	Mentor	Hein	07/01/09-	\$2,037,745
T32ES011564	Sciences			06/30/14	
	Training Program				
NIH	Novel therapies in alcoholic	Co-I	McClain	10/01/12-	\$1,554,829
U01AA021901	hepatitis University of Louisville			09/31/17	
NIH	Effect of dietary fat on the	Co-I	Watson	05/25/12-	\$449,750
R21ES021311	hepatotoxicity of environmental			04/30/14	
	arsenic				
UofL IRIG	Role of ECM and inflammatory	PI	Arteel	07/01/12-	\$15,000
CEG	remodeling in alcohol-induced			06/30/13	
mechanism	liver and lung damage				
Arteel, Juliane B	eier				_
NIH	Enhancement of NAFLD risk by	PI	Beier	04/01/13-	\$ 483,804
K01DK096042	vinyl chloride: interaction of gut-			03/31/18	
	liver-adipose axis				
Benz, Fred					

# Pharmacology & Toxicology 2013 Active Grants

DoD US Army	Biomarkers of Exposure and	PI		9/27/2010 -	\$558,000
W81XWH-10-	Mechanism of Action of Toxic			6/30/2013	
2-0143	Industrial Chemicals (TICs)				
Ceresa, Brian	1	1		1	1
NIH/NIGMS	Endocytic Regulation of EGFR	PI	Ceresa	09/01/10-	\$600,000
R01GM092874	Signaling			08/31/14	<b>*==0000</b>
NIH/NEI	Modulation of EGFR Signaling	PI	Ceresa	01/01/12 -	\$750,000
R01EY021497	to Promote Corneal Wound			12/31/14	
	Healing				
Clark, Geoffrey					
NCI/R01	The Role of the Ras effector	PI		2010-2015	\$900,000
CA133171-	Nore1a in tumor suppression				(directs)
01A2					
NIH Eureka	Oncopigs as a better model for	PI		2010-2014	\$800,000
Award/ 1R01	human cancer				(directs)
CA153132-01					
NIH COBRE	The development of Novel Ras	PI		2013-2015	\$150,000
Pilot Award	antagonists to inhibit cancer				
Davis, Keith	· •		•		•
Owensboro	Development of Lunasin as a	PI	Davis	05/01/2010-	\$ 668,080
Grain	Chemoprevention Agent			12/31/2014	. ,
DoD/USAMR	Plant-Based Expression Systems	Co-I	Wilkers	08/23/2010	\$3,499,000
MC	for New Vaccines and		on	to	+-,,
W81XWH-10-	Therapeutics			10/29/2015	
2-0082- CLIN 1					
and CLIN 2					
Kentucky	Continued Development of the	PI	Davis	7/1/2011 to	\$78,059
soybean	Soybean-Derived Peptide		2	6/30/2012	<i><i><i>ϕ</i></i>, <i>σ</i>, <i>σ</i>, <i>σ</i>, <i>σ</i>, <i>σ</i>, <i>σ</i>, <i>σ</i>, <i></i></i>
Promotion	Lunasin as an Anticancer Agent			0,00,2012	
Board					
Kentucky	Continued Development of the	PI	Davis	7/1/2012 to	\$78,559
soybean	Soybean-Derived Peptide		2 4 1 1 5	6/30/2013	<i><i><i>ϕ</i></i>,<i><i>ϕ</i>,<i>ϕ</i>,<i>ϕ</i>,<i>ϕ</i>,<i>ϕ</i>,<i>ϕ</i>,<i>ϕ</i>,<i>ϕ</i>,</i></i>
Promotion	Lunasin as an Anticancer Agent			0,00,2010	
Board					
Kentucky	Continued Development of the	PI	Davis	7/1/2013 to	\$50,000
soybean	Soybean-Derived Peptide		24110	6/30/2014	+20,000
Promotion	Lunasin as an Anticancer Agent			5,20,2011	
Board					
Kentucky	Plant-Based Expression of an	PI	Davis	7/1/2012-	\$50,000
Science and	Alpha-1 Antitrypsin Biosimilar		Suris	6/30/2013	<i>420,000</i>
Engineering				NCE to	
Foundation				12/31/13	
Gupta, Ramesh	I	1	I	12/01/10	1
NCI	Breast Cancer Chemoprevention	PI	Gunta	04/07 -	\$1,416.820
CA-118114	Strategies	11	Gupta	04/07 - 03/13	φ1,410.020
CA-110114	Sudicyles			03/13	
NCI	Prost Concer Chamannessortian	DI	Curato	07/07	\$1 406 000
NCI	Breast Cancer Chemoprevention	PI	Gupta	07/07 -	\$1,406,000
CA-125152	Potential of Common Spices			05/14	

KY Lung Ca Res. Board	Activation of the Par-4 Extrinsic Pathway for Suppression of Lung Cancer	PI	Gupta	12/10 - 11/13	\$150,000
U.S. Highbush Blueberry Council	Prevention of Breast Cancer by Blueberry	PI	Gupta	07/11 - 6/13	\$91,431
UofL CEG	Prevention & Treatment Strategies for Lung Cancer Recurrence & Metastasis	PI	Gupta	02/12 - 01/13	\$15,000
R43-CA- 162417	Sustained, Target Delivery for Treatment of Cervical Pathologies	PI	Gupta Spencer	07/12 - 12/14	\$300,000
U.S. Highbush Blueberry Council	Therapeutic Activity of Blueberry Against Lung Cancer	PI	Gupta	08/13 - 07/14	\$74,270 (Directs)
KY Matching	This grant is a supplement to the SBIR Phase I grant	PI	Gupta	01/13-06/14	\$150,000 (Directs)
Coulter Foundation	Treatment of Cervical Pathologies by Curcumin Delivered Locally by a Polymeric Device	PI	Gupta Parker O'Toole	7/13 - 6/14	\$138,714 (Total)
Hein, David					
NIH, NIEHS T32-ES011564	UofL Environmental Health Science Training Program	PI	Hein	07/1/09- 06/30/14	\$1,999,550
R25- CA134283- 01A1	University of Louisville Cancer Education Program	PI	Hein	9/14/12- 08/31/16	\$1,560,990
NIEHS T35 ES014559	Summer Environmental Health Sciences Training Program	Mentor	Prough	04/01/2011– 03/31/2016	\$175,814
Hurst, Harrell					
US Army Med Research W81XWH-10- 2-0143	Biomarkers of Exposure and Mechanism of Action of Toxic Industrial Chemicals (TICs)	Co-I	Benz	09/27/2010 - 06/30/2013	\$558,000
Kang, Y. James NIH-NIAAA,	Mechanisms of Probiotics in	Co-I	Wenke	07/01/14-	\$1,500,000
1R01AA023190	Alcoholic Liver Disease		Feng	06/30/19	
Kidd, LaCreis NIH, NIEHS	UofL Environmental Health	Mentor	Hein	07/1/09-	\$1,999,550
T32-ES011564	Science Training Program	Mentor	Tiem	06/30/14	\$1,333,330
R25- CA134283- 01A1	University of Louisville Cancer Education Program	Co-I, Cancer Educatio n Coordina tor,	Hein	9/14/12- 08/31/16	\$1,560,990

		Mentor			
Lukashevich, Igo	or				•
NIH/R01	Development of New Bivalent Cr	oBI-		04/01/2011-	\$3,964,538
AI093450	Protective Arenaviral Vaccines			03/31/2016	
NIH/R43	Novel DNA-launched Attenuated	Co-I	Pushko	03/01/2012-	\$171,849
AI094863	Vaccine for VEE Virus			05/31/2014	
(SBIR)		C. I	D1-1	04/01/2012	¢5( 012
NIH/R43 AI094700	Trivalent Arenaviral Vaccine Bas		Pushko	04/01/2012-07/30/2013	\$56,213
(SBIR)	Virus-Like Particle Vectors (VLP	Vs)		07/30/2013	
NIH/R03	A Novel DNA-launched Live Att	God	Pushko	03/01/2012 -	\$37,250
AI094159		ermated	I ushko	08/31/2012	φ37,230
11071107	Chikungunya Vaccine			00/01/2011	
Matoba,					
NIH NIAID	Plant-produced Actinohivin as a	PI	Matoba	06/10/10-	\$1,175,000
Microbicide	Candidate HIV Microbicide			06/30/15	(total direct
Innovation					costs)
Program V					
/R21/R33					
AI088585					
DoD	Plant-Based Expression Systems	Subproj	Wilkers	08/23/2010-	\$390,000
USARMC/	for New Vaccines and	PI	on	08/22/2013	(total
W81XWH-10-	Therapeutics				subproj
2-0082 CLIN 1		~			direct costs)
DoD	Plant-Based Expression Systems	Subproj	Wilkers	9/30/2011-	\$1,748,000
USARMC/	for New Vaccines and	PI	on	10/29/2015	(total direct
W81XWH-10-	Therapeutics				costs)
2-0082 CLIN 2 Brown Cancer	Immunotherapoutic potential of	PI	Matoba	07/18/11-	\$170,000
Center	Immunotherapeutic potential of plant-made CTB against colitis	P1	Matoba	12/31/13	(total direct
Helmsley Trust	and colon cancer			12/31/13	costs)
Program					(03(3)
/G2142					
DoD	Development of Novel Vaccines	Member	Wilkers	03/15/09-	\$1,680,000
USARMC/	and Therapeutics Using Plant-		on	03/14/13	(total direct
W81XWH-09-	Based Expression Systems				costs)
2-022	1 J				,
Nerland, Donald					
DoD US	Biomarkers of Exposure and Me	chaoilm	Benz	9/27/201	\$558,000
Army	of Action of Toxic Industrial Che	micals		0 -	
W81XWH-	(TICs)			6/30/201	
10-2-0143				3	
Palmer, Kenneth			1	I	
University of	Griffithsin-based microbicides	PI	Palmer	03/01/2013	\$30,000
	for HIV prevention – Bridge			-	
Louisville					
Louisville School of Medicine	Grant			02/28/2014	

Harry and Leona Helmsley Charitable Trust	Pan-oncogenic HPV vaccine	PI	Palmer	08/01/2011- 10/31/2013	\$340,000
NIH/NIAID R33 AI088585	Plant-produced Actinohivin as a Candidate HIV Microbicide	Co-I	Matoba	06/01/2012- 5/31/2015	\$1,350,000
DoD/USAMR MC W81XWH-10- 2- 0082- CLIN 1	Plant-Based Expression Systems for New Vaccines and Therapeutics	PI of sub- projec	Wilkers on	08/23/2010- 08/22/2013	\$1,751,000
DoD/USAMR MC W81XWH-10- 2- 0082- CLIN 2	Plant-Based Expression Systems for New Vaccines and Therapeutics	PI of sub- projec	Wilkers on	9/30/2011- 10/29/2015	\$1,748,000
Sankar, Uma				•	•
American Cancer Society	CaMKK2 Inhibition in Palliative Care of Advanced Prostate Cancer Patients	PI	Sankar	07/01/2013- 06/30/2017	\$720,000 (Total Costs)
Department of Defense CDMRP Discovery Award /PR121604	CaMKK2 Inhibition in Enhancing Bone Fracture Healing	PI	Sankar	08/15/2013- 03/14/2015	\$187,000 (Total Costs)
Molecular Targets Phase III CoBRE Pilot Project	CaMKK2 Inhibition as a Dual- Hit strategy in the prevention of prostate cancer growth and ADT- induced bone loss	PI	Sankar	11/13/13 – 07/01/15	\$150,000 (Total Costs)
UofL Office of the Exec. VP for Research and Innovation - Competitive Enhancement Grant	Role of Calmodulin-dependent protein kinase kinases in bone remodeling	PI		09/01/12 – 08/31/13	\$15,000
Brown Cancer Center/ Helmsley Trust Program	Role of Calmodulin-Dependent Protein Kinase Signaling in Hematopoiesis	PI		06/01/12- 05/31/14	\$120,000
IOIC100629X0 4 Owensboro Grain Company	Development of Lunasin as a Chemoprevention Agent	Co-I	Keith Davis	05/01/2010 to 11/01/2013	\$ 316,388
DoD/USAMR MC W81XWH-10- 2-0082- CLIN 1	Plant-Based Expression Systems for New Vaccines and Therapeutics <u>Sub-Project</u> : Ca <sup>2+</sup> /Calmodulin dependent protein kinases in	Sub- Project PI	Wilkers on	08/23/10 – 08/22/13	\$1,751,000 Sub-project: \$389,505

	early embryonic neuronal				
	development				
DoD/USAMR	Plant-Based Expression Systems	Sub-	Wilkers	9/30/2011-	\$1,748,000
MC	for New Vaccines and	Project	on	10/29/2015	
W81XWH-10-	Therapeutics	PI			
2-0082- CLIN 2	Sub-Project: Ca <sup>2+</sup> /Calmodulin				
	dependent protein kinases in				
	vaccine-related immunogenicity				
NIH R25-	University of Louisville Cancer	Mentor	Hein	09/14/11 -	\$1,543,610
CA134283	Education Program			08/30/16	total costs
Siskind, Leah					
R01DK093462	Targeting Ceramide-induced	PI	Siskind	09/17/2012-	\$1,599,095
	Kidney Cell Apoptosis and			03/31/2017	
	Necrosis for the Treatment of				
	Acute Kidney Injury				
Song, Zhao-Hui		1			
T32ES11564	UofL Environmental Health	Faculty	David	7/1/09 -	\$ 2,037,745
	Sciences Training Program	Mentor	W. Hein	6/30/14	
	•				
States, J. Christo		DI		10/1/11	<b>*75</b> 000
KLCRP	Role of REV1 in Carcinogen	PI	States	12/1/11 - 5/22/12	\$75,000
~	Induced Lung Cancer		~	5/30/13	<b>*</b> • <b>- - - - - - - - - -</b>
SoMRC	Novel Cancer	PI	States	12/1/11 -	\$15,000
	Chemotherapeutics Targeting			5/30/13	
	Mitosis				
NIH-NIEHS /	Atherogenic Mechanisms Of	Co-I	Srivasta	6/15/09 -	\$1,641,792
R01ES017260-	Arsenic		va	3/31/14	
04					
EVPRI CEG	Differential miRNA expression	PI	States	9/1/13 -	\$15,000
	& progression of arsenic induced			3/31/14	
	skin cancers				

# **RESEARCH GRANTS SUBMITTTED**

# Faculty with Primary Appointments

# Grants Submitted Pharmacology & Toxicology, 2013

Agency/	Title	Role	PI	Project	Budget Award
Number				Period	
Arteel, Gavin					
NIAAA	Prenatal alcohol exposure: impact on insulin signaling pathways	Co-I	Neal	07/01/13- 06/30/18	\$1,875,000
NIEHS	Developmental cigarette smoke exposure: impact on offspring gut-liver axis function	Co-I	Neal	07/01/13-	\$412,500

NIEHS	Gut-liver interaction in arsenic- enhanced obesity-induced liver disease	PI	Artee 1	07/01/13- 03/31/18	\$1,875,000
NIAAA	Prenatal Alcohol Exposure: Impact on Gut Function	Co-I	Neal	10/01/13- 9/30/15	\$412,500
NIEHS	Blackleaf Chemical Biorepository: Characterizing exposure and health effects	Co-I	Cave; Prou gh	11/01/13- 10/31/15	\$412,500
NIAAA	Nutrition, Gut Flora/Intestinal Dysfunction in Alcohol-Induced Organ Injury	Pilot Core Director; Proj 3 MPI	McCl ain	12/01/13- 11/30/18	\$9,000,000
NIEHS	GI microbiome in arsenic- enhanced obesity-induced liver diseases	PI	Artee 1	12/01/13- 11/30/16	\$900,000
NIAAA	Role of ECM and inflammatory remodeling in alcohol-induced liver and lung damage	PI	Artee 1	12/01/13- 11/30/18	\$1,875,000
NIAAA	Gestational alcohol exposure: impact of bacteria community on the neonate	Co-I	Neal	07/01/14- 06/30/16	\$412,500
NICHD	CSE: gut microbiome modulation of hepatic gluconeogenesis	Co-I	Neal	07/01/14- 06/30/16	\$412,500
NIAAA	FAS: Impact of gut microbiome on hepatic lipid function	Co-I	Neal	07/01/14- 06/30/19	\$1,875,000
NIDDK	Therapeutics development for hepatic fibrosis	Subcontr act PI	Maitr a	09/01/14- 08/31/19	\$504,656 (subcontract)
NIEHS	Environmental Chemicals and Liver Disease (R13 mechanism)	Co-I	Cave	2014	\$15,430
Arteel, Juliane B	Seier				
NIEHS superfund P42	Environmental Exposure and Cardiometabolic Disease	Co-I	Sriva stava	04/01/14- 03/31/18	\$500,666 (proj.)
Ceresa, Brian					
NIH/NIGMS R01GM092874	Endocytic Regulation of EGFR Signaling	Co-PI	Ceres a/P. Bates	04/01/14 – 03/31/19	\$ 1,875,000
DoD	Modulation of EGFR Signaling to Promote Corneal Wound Healing	M-PI	Ceres a/P. Bates	07/01/14 – 12/31/17	\$750,000
NIH/NIGMS R01GM092874	In vivo Analysis of Dysregulated EGFR Trafficking	PI	Ceres a	07/01/14- 06/30/19	\$ 1,875,000

NIH/NCI	Identification of molecular targets in pancreatic cancer for novel agents K22/K29	Co-I	McN ally	04/01/14 – 03/31/19	\$ 1,875,000
Clark, Geoffrey				1	1
NIH	A porcine model of ovarian cancer	PI	Clark	2014-2019	\$900,000 direct
DOD	Rechanneling Ras to destroy prostate cancer.	PI	Clark	2014-2017	\$360,00 direct
KLCRP	Novel Ral inhibitors for lung cancer	PI	Clark	2014-2016	\$150,000 direct
Davis, Keith	1	1		•	1
Ky soybean Promotion Board	Continued Development of the Soybean-Derived Peptide Lunasin as an Anticancer Agent	PI	Davis	7/1/2013 - 6/30/2014	\$50,000
Owensboro Grain	Development of Lunasin as a Chemoprevention Agent	PI	Davis	1/1/2014 - 12/31/2014	\$171,929
NIH/NCI	Enhancing anti-tumor immunity of NK cells by lunasin for cancer immunotherapy	Co-I	Chan g	7/1/2014 - 6/30/2016	\$100,000 direct costs \$29,159 to KRD
NIH/NCI	Targets and mechanisms of the chemopreventive soy peptide lunasin in lung cancer	PI	Davis	12/1/2013 - 11/30/2015	\$275,000 direct costs
Gupta, Ramesh					
NCAAM/NCI R01-AT-07428	Inhibition of Lung Cancer by Berry Polyphenolics	PI	Gupt a	4/13-3/18	\$2,256,809
NIH Research Project Grant (Parent R01)	Inhibition of Cigarette Smoke- Mediated Lung Cancer by Berry Bioactives	PI	Gupt a	7/14-6/19	\$2,506,308
NIH Transformative Research Awards (R01)	Exosomal Drug Delivery for Prevention and Treatment of Lung Cancer	PI	Gupt a	7/14-6/19	\$3,528,192
DOD Breast Ca Res Prog Breakthrough Award	Prevention and Treatment of Breast Cancer by Blueberry Anthos	PI	Gupt a	7/14-6/17	\$1,039,962
NIH Research Project Grant (Parent R01)	Adjuvant Therapy for Breast Cancer	PI	Gupt a	7/14-6/19	\$2,603,242
Hein, David NCI R25- CA011564 (non-competing renewal)	University of Louisville Cancer Education Program	PI	Hein	09/01/2013- 08/31/2014	\$274,671
NIH/NIEHS T32- ES011564	UofL Environmental Health Sciences Training Program	PI	Hein	07/01/2013 - 06/30/2014	\$425,838

UofL undergraduate Internship	PI	Hein	05/01/2013	\$11,000
			_	+,
			04/30/2014	
Environmental Exposure and	Co-I	Sriva		\$10,457,421
	001		_	¢10,107,121
		Starta	03/31/2018	
	1			1
Mechanisms of Probiotics in	Co-PI	Feng	07/01/14-	\$1,500,000
Alcoholic Liver Disease		_	06/30/19	
	PI	Kidd	6/15/2013-	15,000
			5/15/2013	
r				1
Advanced Multivalent Lassa	PI		05/1/2014-	\$5,556,382
Virus Vaccine			04/30/2019	
				1
	PI	Mato	7/01/14-	\$2,436,233
		ba		. , ,
	PK/PD	Palm	7/01/14 -	\$15,500,390
				\$10,000,000
		C1	0, 50, 17	
	Leuder			
			1	
Assessing the effects of	PI	Palm	07/01/2014	\$2,665,393
griffithsin on the female genital		er	-	
tract mucosal environment			06/30/2018	
Cuiffithain based Destal	PI	D 1	07/01/2014	
Griffinnsin-Dased Rectal	PI	Palm	07/01/2014	\$15,500,392
Microbicides for PREvention of	PI	er Palm	07/01/2014	\$15,500,392
	P1		- 06/30/2019	\$15,500,392
Microbicides for PREvention of	F1		_	\$15,500,392
Microbicides for PREvention of Viral ENTry (PREVENT)		er	- 06/30/2019	
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent	PI		- 06/30/2019 04/01/14-	\$15,500,392 \$1,909,513
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone		er	- 06/30/2019	
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling	PI	er Sank ar	- 06/30/2019 04/01/14- 12/31/19	\$ 1,909,513
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone		er	- 06/30/2019 04/01/14- 12/31/19 11/13/13 -	
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling	PI	er Sank ar	- 06/30/2019 04/01/14- 12/31/19	\$ 1,909,513
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling CaMKK2 Inhibition as a Dual-	PI	er Sank ar Sank	- 06/30/2019 04/01/14- 12/31/19 11/13/13 -	\$ 1,909,513
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling CaMKK2 Inhibition as a Dual- Hit strategy in the prevention of	PI	er Sank ar Sank	- 06/30/2019 04/01/14- 12/31/19 11/13/13 -	\$ 1,909,513
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling CaMKK2 Inhibition as a Dual- Hit strategy in the prevention of prostate cancer growth and	PI	er Sank ar Sank	- 06/30/2019 04/01/14- 12/31/19 11/13/13 -	\$ 1,909,513
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling CaMKK2 Inhibition as a Dual- Hit strategy in the prevention of prostate cancer growth and ADT-induced bone loss CaMKK2 Inhibition in ADT-	PI PI	er Sank ar Sank ar	- 06/30/2019 04/01/14- 12/31/19 11/13/13 - 07/01/15	\$ 1,909,513 \$150,000
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling CaMKK2 Inhibition as a Dual- Hit strategy in the prevention of prostate cancer growth and ADT-induced bone loss	PI PI	er Sank ar Sank ar Sank ar	- 06/30/2019 04/01/14- 12/31/19 11/13/13 - 07/01/15 12/10/13-	\$ 1,909,513 \$150,000
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling CaMKK2 Inhibition as a Dual- Hit strategy in the prevention of prostate cancer growth and ADT-induced bone loss CaMKK2 Inhibition in ADT- induced Osteoporosis and	PI PI	er Sank ar Sank ar Sank ar	- 06/30/2019 04/01/14- 12/31/19 11/13/13 - 07/01/15 12/10/13-	\$ 1,909,513 \$150,000
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling CaMKK2 Inhibition as a Dual- Hit strategy in the prevention of prostate cancer growth and ADT-induced bone loss CaMKK2 Inhibition in ADT- induced Osteoporosis and Prostate Cancer Growth	PI PI PI	er Sank ar Sank ar Sank ar	- 06/30/2019 04/01/14- 12/31/19 11/13/13 - 07/01/15 12/10/13- 11/30/15	\$ 1,909,513 \$150,000 \$415,343
Microbicides for PREvention of Viral ENTry (PREVENT) Role of Calmodulin dependent protein kinase kinases in bone remodeling CaMKK2 Inhibition as a Dual- Hit strategy in the prevention of prostate cancer growth and ADT-induced bone loss CaMKK2 Inhibition in ADT- induced Osteoporosis and	PI PI	er Sank ar Sank ar Sank ar	- 06/30/2019 04/01/14- 12/31/19 11/13/13 - 07/01/15 12/10/13-	\$ 1,909,513 \$150,000
	Alcoholic Liver Disease Alcoholic Liver Disease r Advanced Multivalent Lassa Virus Vaccine ki Development of a Bispecific Entry/Fusion Inhibitor for a Topical HIV Microbicide Griffithsin-based Rectal Microbicides for PREvention of Viral ENTry (PREVENT) Assessing the effects of griffithsin on the female genital	ProgramImage: Constraint of the system of the s	ProgramCo-ISriva stavaEnvironmental Exposure and Cardiometabolic DiseaseCo-ISriva stavaMechanisms of Probiotics in Alcoholic Liver DiseaseCo-PIFengMechanisms of Probiotics in Alcoholic Liver DiseaseCo-PIFengMechanisms of Probiotics in Alcoholic Liver DiseasePIKiddMechanisms of Probiotics in Alcoholic Liver DiseasePIKiddMechanisms of Probiotics in Alcoholic Liver DiseasePIKiddMechanisms of Probiotics in Alcoholic Liver DiseasePIKiddMato Virus VaccinePIMato baMicrobicidePIMato baGriffithsin-based Rectal Microbicides for PREvention of Viral ENTry (PREVENT)PK/PD Core LeaderPalm erAssessing the effects of griffithsin on the female genital tract mucosal environmentPIPalm er	ProgramImage: ProgramImage: ProgramImage: ProgramImage: ProgramEnvironmental Exposure and Cardiometabolic DiseaseCo-ISriva stava04/01/2014 - 03/31/2018Mechanisms of Probiotics in Alcoholic Liver DiseaseCo-PIFeng Feng07/01/14- 06/30/19Mechanisms of Probiotics in Alcoholic Liver DiseaseCo-PIFeng Feng07/01/14- 06/30/19Mechanisms of Probiotics in Alcoholic Liver DiseasePIKidd6/15/2013- 5/15/2013SrPIVirus Vaccine05/1/2014- 04/30/2019kiVirus VaccinePI05/1/2014- 04/30/2019kiStateVirus VaccinePIDevelopment of a Bispecific Entry/Fusion Inhibitor for a Topical HIV MicrobicidePK/PD Core LeaderPalm er7/01/14- 6/30/18Griffithsin-based Rectal Microbicides for PREvention of Viral ENTry (PREVENT)PK/PD Core LeaderPalm er07/01/2014 - 0/30/2019Assessing the effects of griffithsin on the female genital tract mucosal environmentPIPalm er07/01/2014 - 06/30/2018

BLR&D VA	The role and regulation of lipid	Co-I	Nowli	4/1/2014-	\$1,119,600
Merit Review	mediators in lupus nephritis.	001	ng	3/31/2018	φ1,119,000
Award			0		
NIGMS, R01	BCL2-like proteins and	Co-I	Beverl	07/01/2014	\$1,875,000
	sphingolipids coordinately		У	- 06/30/19	
	regulate apoptosis				
NIDDK	The role of glycosphingolipids in	PI, 25%	Siskin	07/01/2014	\$1,875,000
	diabetic nephropathy	effort	d	- 06/30/19	
NIH, JGBCC	Pentose phosphate pathway and	PI	Siskin	10/1/2013-	\$150,000
Molecular Terrests COPPE	glycosphingolipids are novel		d	9/30/2015	
Targets COBRE pilot project	dependencies of cancer				
Alex's	Sphingolipid metabolism as a	Co-I	Beverl	1/2/2014-	\$371,153
Lemonade Stand	novel biomarker and target in	0-1	y	1/2/2014-	ψ571,155
Found for	pediatric leukemia		5	_, _,	
Childhood Ca					
NSF	Cross-talk between BCL2-like	Co-I	Beverl	4/1/2014-	\$1,118,818
	proteins and sphingolipids in		У	3/31/2019	
KODE	apoptosis	DI	DI	07/01/2014	<u> </u>
KSEF	Sphingolipid metabolism as a	PI	PI: Siskin	07/01/2014-	\$30,000
	novel biomarker and therapeutic of pediatric leukemia		d	06/30/2015	
	of pediatrie reakenna		Co-PI:		
			Beverl		
			y		
KSEF	A comprehensive resource to	Co-PI	PI:	07/01/2014-	\$30,000
	study the role of sphingolipid		Beverl	06/30/2015	
	metabolism in cancer biology		y Co-		
			PI:		
			Siskin d		
Song, Zhao-Hui			u		
R21HD080268	Discovery of Novel Ligands for	PI	ZH	4/1/2014-	\$412,500
	GPR3		Song	3/31/2016	
R21DA037919	Allosteric Modulators of CB2	PI	ZH	7/1/2014-	\$412,500
	Cannabinoid Receptor		Song	6/30/2016	
States, J Christo NIEHS /		PI	Stata	12/01/2012	\$412,500
R21ES023627-	Differential miRNA expression & progression of arsenic induced	LI	State s	12/01/2013 -11/30/2015	φ412,300
01	skin cancers		6	11/30/2013	
NIEHS /	Environmental Exposure and	IAC	Sriva	04/01/2014	\$7,007,621
P42ES023716-	Cardiometabolic Disease	member	stava	- 3/31/2019	
01					
KLCRP	Targeting the anaphase	PI	State	1/1/14 -	\$150,000
	promoting complex as lung		S	12/31/15	
	cancer chemotherapy				

NIEHS/ R21ES024024- 01	Black Leaf Chemical Biorepository: Characterizing Exposure and Health Effects	Co-I	Cave	11/1/13- 10/31/17	\$412,500
BCC – CobrePilot Preproposal	Non-tubulin mitosis disrupting chemotherapeutics	PI	State s	10/1/2013	\$75,000

# **INVITED SCIENTIFIC PRESENTATIONS Faculty with Primary Appointments**

# Arteel, Gavin:

1. Research seminar, 05/13 "And the hits keep coming: interactions that modify the risk of fatty liver disease," University of Louisville, Center for Obesity and Diabetes Research.

2. Research seminar, 03/13 "Hit-by-hit (by hit): new potential mechanisms in chronic liver diseases," University of Arkansas, Medical School, Little Rock, AR.

3. Seminar, 06/13 "How to get your papers published in good journals." University of Louisville, R25 Cancer Education Program, Louisville, KY.

4. Research seminar, 09/13 "And the hits keep coming: interactions that modify the risk of fatty liver disease," Kansas University Medical College, Kansas City, MO.

5. Seminar, 11/13 "Experimental design and hypothesis testing." University of Louisville School of

Medicine, Distinction in Research Program, Louisville, KY.

# Arteel, Juliane Beier:

1. Research seminar, 09/11/13, Liver disease: hidden risk for viral hemorrhagic fever? University of Louisville, Center for Predictive Medicine, University of Louisville, KY.

#### Ceresa, Brian:

1. February 2, 2013: Department of Ophthalmology and Vision Sciences, University of Louisville "Promoting Corneal Epithelial Homeostasis by Modulating Epidermal Growth Factor Receptor Activity".

2. October 1, 2013 – University of Kentucky, Department of Biochemistry, "EGFR trafficking in the Corneal Epithelium"

#### Davis, Keith:

1. Anticancer effects of the soy-derived peptide lunasin. 2013. Department of Biology, IUPUI, Indianapolis, Indiana

2. Development of novel cancer chemoprevention agents from soybean. 2013. Department of Biological Sciences, Georgetown College, Georgetown, Kentucky

#### Gupta, Ramesh:

1. "Therapeutic Potential of Blueberry Anthos ('Color' Therapy)" at the Berry Health Benefits Symposium, June 18-20, Charlotte, North Carolina

#### Hein, David:

1. Use of Cryopreserved Human Hepatocytes to Investigate Genetic Variability in Drug and Xenobiotic Metabolism and Toxicity. Annual meeting of the Society of Toxicology, San Antonio, Texas, March 2013.

2. Cryopreserved Human Hepatocytes to Investigate Genetic Variability in Drug and Xenobiotic Metabolism and Toxicity. West China Hospital at Sichuan University, Chengdu, China, May 2013.

3. Pharmacogenomics and Molecular Epidemiology: Personalized Medicine and Environmental Health. Universite Paris Diderot, Paris, France, September 2013.

4. Acetylation Polymorphisms as Modifiers of Environmental Disease. Department of Environmental Health, University of Cincinnati School of Medicine, Cincinnati, Ohio, October 2013.

5. NAT2 Polymorphisms and Disease Risk: Implications of Genetic Heterogeneity in the Slow Acetylator Phenotype. Sixth International Workshop on the Arylamine N-acetyltransferases Toronto, Canada, October 2013.

6. Translation of Laboratory Research Findings Towards the Assessment of Tobacco-related Cancer Risk in Populations and Individuals. School of Public Health and Information Sciences, University of Louisville, Louisville, Kentucky, October 2013.

#### Kang, Y. James:

1. Invited Speaker, Symposium "Contemporary Approaches for Safety Assessment of the Complex Mixtures of Natural Products" at the 52rd annual meeting of the Society of Toxicology, San Antonio, TX, March 10-14, 2013. "Herbogenomics as a translational method for the safety assessment of the complex mixtures in TCM".

#### Lukashevich, Igor:

1. The BIT's 5th World Congress of Vaccine, Hangzhou, China, March 18-20, 2013.

2. Keystone Symposia on Molecular and Cellular Biology, Advancing Vaccines in the Genomics Era. Oct 31- Nov 4, 2013, Windsor Barra Hotel, Rio de Janeiro, Brazil.

3. Invited Speaker: Defense Threat Reduction Agency (DTRA), Fort Belvoir, VA. Advanced Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. August 21, 2013,

4. Invited Speaker: The Sealy Center for Vaccine Development, UTMB, Galveston, Texas. Novel Vaccine Technologies to Control Viral Emerging Infections. Dec 11, 2013.

# Matoba, Nobuyuki:

1. "Molecular farming of novel antiviral biotherapeutics" Molecular Targets seminar, University of Louisville Brown Cancer Center, May 16, 2013.

2. "Development of biopharmaceuticals by molecular farming" Invited seminar, University of Tokyo Faculty of Agriculture, June 17, 2013.

3. "Molecular farming of biopharmaceuticals" Invited seminar, Iwaki Meisei University Faculty of Pharmacy, June 18, 2013.

4. "Molecular farming of biopharmaceuticals" Invited seminar, Kyoto University Graduate School of Agriculture, June 21, 2013.

5. "Using Plants to Kill Viruses" Brown Cancer Center Retreat, University of Louisville, October 25, 2013.

# Sankar, Uma:

1. The Multifaceted CaMKK2: One Kinase – Multiple Possibilities. *Molecular Targets Program,* JGBCC, University of Louisville, February 21, 2013.

2. Regulation of Mitochondrial Fission/Fusion Dynamics by GFER: Implications in Stem/Progenitor Cell Survival. *Kentucky Spinal Cord Injury Research Center*, University of Louisville, February 28, 2013.

3. CaMKK2 in Osteoblast and Osteoclast Differentiation and Function. Bone Club, Department of Anatomy and Cell Biology, Indiana University Purdue University School of Medicine, Indianapolis, IN, August 28, 2013.

# Siskind, Leah:

1. Research seminar, 10/13 "Role of glycosphingolipids in diabetic nephropathy." University of Louisville, Department of Nephrology, Research Seminar Series, Louisville, KY.

2. Invited Talk, 10/13 "Biophysics of Sphingolipids: a historical perspective." *International Ceramide Conference*, Long Island, NY.

3. Research seminar, 10/13 "Sphingolipid metabolism as a therapeutic target for disease." MD/PhD program seminar series, University of Louisville, Louisville, KY.

4. Research seminar, 09/13 "Sphingolipid metabolism as a therapeutic target for cancer." University of Louisville, Molecular Targets, James Graham Brown Cancer Center, Louisville, KY

5. Invited Talk, 07/23/13 "Role of Sphingolipids in Renal Aging." NIH Workshop: Ceramides in Aging, at the National Institutes of Aging, Bethesda, MD. The purpose of this workshop was to to bring together experts in the field of ceramides and aging to evaluate the current state of the art and to determine what are the challenges and opportunities in furthering the research in this area.

### **States, J. Christopher:**

1. "Developmental Arsenic Exposure and Dysregulation of Liver Gene Expression", International Congress on Environmental Mutagens, Foz do Igussu, Brazil, November 3-8, 2013

# INVENTIONS, DISCLOSURES, LICENSE/OPTION AGREEMENTS, PATENT AWARDS, AND BUSINESS STARTUPS Faculty with Primary Appointments

# Davis, Keith:

**Business Startups** 

- continue to serve as the CEO of Planta BioProducts, LLC. Recent efforts have gone towards business development activities.

#### Gupta, Ramesh:

- U.S. Continuation-in-Part Patent Application, ser. no. 13/429,601; filed March 26, 2013. R.C. Gupta, M. Vadhanam and F. Aqil

- Milk-derived Microvesicle Compositions and Related Methods. R.C. Gupta, R. Munagala, F. Aqil and J Jeyabalan; provisional application filed in February 2013

# Kidd, LaCreis:

- "Genetic Determinants of Prostate Cancer", UofL Research Disclosure ref. #11078; Impact of chemokine-related sequence variants and prostate cancer risk; U.S. National Phase Application of International Patent Application No. US 2013/0323734 A1; Publication date: December 5, 2013; (www.google.com/patents/US20130323734)

- "Innate Immunity Markers of Cancer", UofL Research Disclosure ref. #10012; Impact of innate immunity-related sequence variants and prostate cancer and/or breast cancer; U.S. National Phase Application of International Patent Application No. US 2013/0116139 A1; Publication date: May 9, 2013; (www.google.com/patents/US20130116139)

#### Matoba, Nobuyuki:

- Patent Applications:

U. S. Provisional Patent Application Serial No. 61/763.366; Title: Methods for producing antibodies

#### Palmer, Kenneth:

- Invention disclosure, by Palmer KE, Fuqua J, and Matoba N, which led to U. S. Provisional Patent Application Serial No. 61/846,906 Title: Compositions for Mucusal Delivery, Useful for Treating Papillomavirus Infections

- Acted as Managing Director of Intrucept Biomedicine LLC, Owensboro, Kentucky

#### Siskind, Leah:

- 07/2013, Provisional Patent, P1210, Attorney Docket No. 10075-019PV1, Altered glycosphingolipid metabolism in nephritis

# **DEPARTMENTAL COURSES**

- Medical Pharmacology course to second year medical students. Drs. Mike Williams and Steve Myers served as course directors.
- Pharmacology and Dental Therapeutics course to dental students. Dr. David Hein served as course director.
- Pharmacology course to second year students in the Dental Hygiene Program. Dr. Steve Myers served as course director.
- Basic Pharmacology course for undergraduate students. Dr. Steven Myers served as course director.
- The Department team taught several courses for graduate students. The individual courses and course directors included:
  - PhTx 660 Principles of Drug and Chemical Action (Dr. Benz)
  - PhTx 606 Pharmacology Seminar (Dr. Nerland)
  - PhTx 661 Molecular Toxicology (Drs. Prough and Gavin Arteel)
  - PhTx 625 Scientific Writing (Dr. Gavin Arteel)
  - PhTx 655 Neuropharmacology (Drs. Rowell and Song)
  - PhTx 656 Cardiovascular and Renal Pharmacology (Drs. Benz and Williams)
  - PhTx 657 Endocrine and Metabolic Pharmacology (Dr. Arteel)
  - PhTx 658 Selective Toxicity and Chemotherapy (Drs. Hurst and Nerland)
  - PhTx 672 Research Methods in Pharmacology & Toxicology I (Drs. Song and States)
  - PhTx 673 Research Methods in Pharmacology & Toxicology II (Drs. Song and States)
  - PhTx 674 Research Methods in Pharmacology & Toxicology III (Drs. Song and States)
  - PhTx 675 Research Methods in Pharmacology & Toxicology IV (Drs. Song and States)
  - PhTx 618 Biostatistics (Dr. Kidd)

# **STANDING COMMITTEES**

# Graduate Student Affairs and Curriculum Committee

Dr. Peter Rowell (Chair) Dr. Gavin Arteel (2013) Dr. Uma Sankar (2014) Dr. Brian Ceresa (2015) Student rep: Pritesh Kumar Student rep: Veronica Massey

#### **Graduate Student Admissions and Recruitment Committee**

Dr. Chris States (Chair) Dr. Ken Palmer (2013) Dr. La Creis Kidd (2014) Dr. Ramesh Gupta (2015) Dr. Steve Myers (2016)

### **SIBUP/Grievance Committee**

Dr. Peter Rowell (Chair) Dr. Harrell Hurst (2013) Dr. Ramesh Gupta (2014) Dr. Joe Song (2015)

#### **Teaching Evaluation Committee**

Dr. Mike Williams (Chair) Dr. Fred Benz (2013) Dr. Don Nerland (2014) Dr. Harrell Hurst (2015)

#### **Seminar Committee**

Dr. Don Nerland (Chair) Dr. Fred Benz (2013) Dr. Igor Lukashevich (2014) Dr. Gavin Arteel (2015)

# **Events Committee**

Dr. La Creis Kidd (Chair) Dr. Nobuyuki Matoba (2013) Dr. Keith Davis (2014) Dr. Juliane Arteel (2015) Student rep: Pritesh Kumar

#### **Information Technology Committee**

Dr. Gavin Arteel Dr. Fred Benz Dr Harrell Hurst

#### **Department Graduate Students**

Adcock, Scott Al-Eryani, Laila Al-Maqtari, Tareq Aloway, April Avila. Diana Baldauf, Keegan Barton, Chris Belshoff. Alex Carlisle, Samantha Chen, Wei Yang (Jeremy) Cheng, Pei-Hsin (Penny) Dupre, Tess Donde, Hridgandh England, Christopher Finch, Jordan Greenwell, Caleb Grewal, Jaspreet Hallgren, Justin Holz, Gretchen Hudson, Shanice

Jackson, Nicole Jones, Dominique Kurlawala, Zimple Kumar, Pritesh Lasnik, Amanda Massey, Veronica McAllister, Ryan Neely, Aaron Pandit, Harshulkumar Poole, Lauren Pritchard, Zachary Schmidt, Robin Shidal, Christopher Skibba, Melissa Stathem, Morgan Stepp, Marcus Vicary, Glenn Wahlang, Banrida Wechman, Stephen

#### Wenzhou Medical University PhD Partnership Signing Ceremony









Peter K. Knoefel Endowed Chair of Pharmacology & Toxicology Professor and Chair, <u>Department of Pharmacology & Toxicology</u> Associate University Provost for Strategic Planning Distinguished University Scholar David W. Hein, PhD Clinical and Translational Research - Room 303 University of Louisville Health Sciences Center 505 South Hancock Street Louisville, Kentucky 40202-1617

Phone: 502-852-6252 Email: <u>d.hein@louisville.edu</u> Website: www.louisville.edu/faculty/dwhein01

#### AGREEMENT FOR PhD PARTNERSHIP IN PHARMACOLOGY AND TOXICOLOGY WENZHOU MEDICAL UNIVERSITY AND UNIVERSITY OF LOUISVILLE

The Department of Pharmacology and Toxicology of the University of Louisville and the School of Pharmacy at Wenzhou Medical University intend to enhance relations between the two universities by developing an academic and cultural exchange in teaching, research and other activities. This agreement describes a PhD partnership in which students enter and complete an MS program at Wenzhou Medical University and then transfer to the University of Louisville to complete the requirements for the PhD in pharmacology and toxicology.

Students initially will be admitted into the existing MS program in pharmacology at Wenzhou Medical University. Their course of study at Wenzhou Medical University includes coursework that will substitute for required coursework for the PhD in pharmacology and toxicology at the University of Louisville. Upon completion of the course of study at Wenzhou Medical University, top students will be recommended for transfer to the PhD program in pharmacology and toxicology at the University of Louisville. Upon transfer to the University of Louisville these students will be required to complete presentation/communication courses as well as the remaining required coursework for the PhD in pharmacology and toxicology. The students also will be required to pass applicable qualifying exams, including preparation, presentation and defense of their PhD dissertation proposal. Upon successful defense of their PhD proposal, the students will engage in research towards the preparation, presentation, and defense of their PhD dissertation. Following successful completion of all required courses at the University of Louisville and successful defense of their PhD dissertation, the student will be awarded the PhD in pharmacology and toxicology and toxicology from the University of Louisville.

The projected number of students will depend upon the quality of the students interested and the capacity of University of Louisville faculty members to incorporate these students into their laboratory research programs.

Requirements for transfer of students from Wenzhou Medical University into the PhD program in pharmacology and toxicology at the University of Louisville include:

- 1. Letter of application from the student acknowledging that the student is responsible for all required tuition and fees including health insurance to be paid to the University of Louisville.
- 2. Transcript detailing coursework completed at Wenzhou Medical University.
- 3. Electronic copy of MS thesis submitted in partial fulfillment for the MS degree at Wenzhou Medical University (if MS thesis was completed).
- 4. Two recommendation letters that include assessment of applicant's competency in written and spoken English. GRE and TOEFL scores are encouraged but can be waived based on interview and recommendation letters.
- 5. Copy of letter from Wenzhou Medical University to the student indicating the amount and terms of financial support to the student from Wenzhou Medical University.
- 6. Transfer of students will be subject to compliance with entry and visa requirements of China, the United States, Wenzhou Medical University and the University of Louisville.
- 7. Interview with member(s) of the University of Louisville faculty.

Courses completed at Wenzhou Medical University will substitute for courses at the University of Louisville. The curricular requirements to be completed at Wenzhou Medical University that substitute for the specific courses at the University of Louisville are listed below with additional details on course objectives and faculty teaching these courses is provided as an attachment.

- 1. Cell Biology (48 class hrs)
- 2. Physiology (78 class hrs)
- 3. Biochemistry (54 class hrs)
- 4. Molecular Biology (32 class hrs)
- 5. Pharmacology (244 class hrs)
- 6. Medical Research Methods (32 class hrs)
- 7. Medical statistics (32 class hrs)
- 8. Completion of an MS degree program awarded by Wenzhou Medical University

Curricular requirements to be taken at the University of Louisville for students transferring to the PhD program in pharmacology and toxicology are shown below (steps 1-4 should be completed in the first year of residency).

- 1. Communication in English (3 credits)
- 2. Scientific Writing (2 credits)
- 3. Research Ethics (1 credit)
- 4. Seminar (1 credit)
- 5. Defense of dissertation proposal (Final Qualifying Exam)
- 6. Presentation and Defense of PhD dissertation
- 7. Award of the PhD in pharmacology and toxicology from the University of Louisville

All instruction and coursework, presentations, examinations and defenses are in English. Curricular requirements at the University of Louisville may be revised as program quality and effectiveness is assessed through faculty teaching and course evaluations, and through the program review process required of all graduate programs at the University of Louisville.

Member(s) of the University of Louisville or Wenzhou Medical University faculty may travel to the partner university to meet with students, faculty, and administrators to discuss curriculum, course quality, students and logistical issues. Travel costs will be borne by Wenzhou Medical University, subject to their approval regarding dates and number of faculty members each visit.

All tuition and fee costs for the PhD program at the University of Louisville, including participation in the health insurance program, is to be paid by the student. Wenzhou Medical University will provide the students funds to pay all applicable tuition and fees at the University of Louisville, including health insurance, and living expenses including travel and housing. A projection of the cost of each entering student for the 3.5 year estimated tenure in the PhD pharmacology and toxicology program at the University of Louisville is shown as an attachment.

Payment for faculty time and effort and for research expenses are the responsibility of the host university (Wenzhou Medical University during the MS program and the University of Louisville upon transfer to the PhD program). No additional support to the student or waiver of required tuition and fees will be provided by the University of Louisville.

Students transferring from Wenzhou Medical University will have access to the full complement of services available to students enrolled at the University of Louisville, including health, sports and recreation, the arts, advising, entertainment, and housing. The International Center at the University of

Louisville provides comprehensive information and serves all international students at the University of Louisville, including those transferring from Wenzhou Medical University.

This agreement shall be effective upon approval by both universities and shall remain in effect indefinitely subject to the right of either institution to withdraw from the agreement by giving no less than one (1) year written notice to the other institution. Any termination shall not affect the obligations already in progress prior to termination.

Any changes or additions to this agreement shall be agreed to in writing by both universities.

#### Signatures for the University of Louisville:

David W. Hein Chair, Department of Pharmacology and Toxicology Associate University Provost for Strategic Planning

Date: December 17, 2013

Beth A. BoehmVice Provost for Graduate AffairsDean, School of Interdisciplinary and Graduate StudiesDate: December 17, 2013

Mordean Taylor-Archer	
Vice Provost for Diversity and International Affairs	Date: December 17, 2013

#### Signatures for Wenzhou Medical University:

Professor Xiaokun Li Vice President Wenzhou Medical University

Date:

Louisville provides comprehensive information and serves all international students at the University of Louisville, including those transferring from Wenzhou Medical University.

This agreement shall be effective upon approval by both universities and shall remain in effect indefinitely subject to the right of either institution to withdraw from the agreement by giving no less than one (1) year written notice to the other institution. Any termination shall not affect the obligations already in progress prior to termination.

Any changes or additions to this agreement shall be agreed to in writing by both universities.

#### Signatures for the University of Louisville:

Nulla David W. Hein

Chair, Department of Pharmacology and Toxicology Associate University Provost for Strategic Planning

Betn a. Bohn

Beth A. Boehm Vice Provost for Graduate Affairs Dean, School of Interdisciplinary and Graduate Studies

Date: December 17, 2013

Date: December 17, 2013

Mordi on Raylor - Arcicia Mordean Taylor - Arcicia

Vice Provost for Diversity and International Affairs

Date: December 17, 2013

#### Signatures for Wenzhou Medical University:

Professor Xiaokun Li Vice President Wenzhou Medical University

ruo Venly

2013-12-1 Date:



# **Tess Dupre**

Home town: Lafayette, LA

B.S., Toxicology Univ. of Louisiana at Monroe



### **Jordon Finch**

### Home town: Hillsboro, MO

M.S., Biological Sciences Southern Illinois Univ. - Edwardsville



# Jaspreet Grewal, M.D.

Home town: Brampton, Ontario

M.D., Christian Medical College, Ludhiana, India M.P.H., Univ. of Illinois - Chicago



# **Shanice Hudson**

### Home town: Indianapolis, IN

B.S., Biology Massachusetts Institute of Technology



# Zimple Kurlawala

Home town: Mumbai, India M.D. – Univ. of Seychelles/American Institute of Medicine M.P.H. – Public Health Education, Western Kentucky University



## **Aaron Neely**

Home town: Nassau, Bahamas

M.S., Biology – University of North Texas B.S., Biology – Paul Quinn College



## Lauren Poole

Home town: Louisville, KY

B.S., Biology (Genetics) University of Louisville



# **Morgan Stathem**

Home town: Burke, VA

B.S., Biological Sciences University of Georgia

(entering as 2nd-year student)



Samantha N. Barry Medical Student University of Louisville School of Medicine Email: <u>snbarr02@louisville.edu</u> Faculty Mentor: Kelly McMasters, MD, PhD Research Project: Identifying serum exosomal microRNA signatures in melanoma patients



Matthew S. Bienick Undergraduate Student Michigan State University Email: <u>mbienick@msu.edu</u> Faculty Mentor: Keith Davis, PhD Research Project: Effects of soy peptide Lunasin on inhibition of melanoma



Harrison M. Black Dental student University of Louisville School of Dentistry Email: <u>hmblac02@louisville.edu</u> Faculty Mentor: David A. Scott, PhD Research Project: Tobacco-induced dysregulation of matrix metalloproteinases in immune cells



Neil Bodduluri Duke University Graduate Email: <u>neilbodduluri@gmail.com</u> Faculty Mentor: David W. Hein, PhD Research Project: Effect of high fat and high fructose diets on MDA-induced carcinogenicity in Nat2 rapid acetylator rats



James A. Bradley Medical Student University of Louisville School of Medicine Email: jabrad07@louisville.edu Faculty Mentor: John W. Eaton, PhD Research Project: Utilizing the humoral response to early-stage lung cancer as a potential biomarker for early diagnosis



**Elizabeth H. Bruenderman** Medical Student University of Louisville School of Medicine Email: <u>chbrue01@louisville.edu</u> Faculty Mentor: Robert C. Martin, MD, PhD Research Project: A true higher risk patient population does exist in idiopathic pancreatic adenocarcinoma



Sean T. Butterbaugh Undergraduate Student University of Louisville Email: <u>stbutt01@louisville.edu</u> Faculty Mentor: James Wittliff, PhD Research Project: A genomic approach to identify clinically relevant gene signatures that underlie favorable response of ILC to aromatase inhibitors



**Cameron Campbell** Undergraduate Student Campbellsville University Email: <u>cmc72191@gmail.com</u> Faculty Mentor: Ramesh Gupta, PhD Research Project: Role of exosomes in tumor growth and metastasis



Matthew Cook Undergraduate student Emory University Email: <u>mcook5@emory.edu</u> Faculty Mentor: Jesse Roman, MD Research Project: Regulation of gene expression by tumor cell stromal interactions



**Tess Dupre** University of Louisiana-Monroe Graduate Rising graduate student University of Louisville Email: <u>dupretv09@gmail.com</u> Faculty Mentor: Lacey R. McNally, PhD Research Project: Detection of pancreatic adenocarcinoma in vivo with S100A9 targeted liposomes



Matthew K. Forsthoefel Medical student University of Louisville School of Medicine Email: <u>mkfors01@louisville.edu</u> Faculty mentor: Paula Bates, PhD Research Project: The role of p38 on AS1411 activity



**Taylor Hermann** Undergraduate Student University of Alabama Email: <u>tnhermann@crimson.ua.edu</u> Faculty Mentor: Hari Bodduluri, PhD Research Project: Exploring the biomarkers of lung cancer metastasis



**Conor Kinslow** Undergraduate Student SUNY-Binghamton Email: <u>ckinslo1@binghamton.edu</u> Faculty Mentor: Andrew Lane, PhD Research Project: Stable isotope resolved metabolomics in lung cancer



Jonathon R. Lindner Medical Student University of Louisville School of Medicine Email: <u>jrlind08@louisville.edu</u> Faculty Mentor: La Creis Kidd, PhD, MPH Research Project: Role of micro-RNA 885-5p in prostate cancer cell lines



Danial Malik Undergraduate Student University of Louisville Email: <u>damali01@cardmail.louisville.edu</u> Faculty Mentor: Paula Bates, PhD Research Project: Developing SOX9 inhibitors



Joshua M. Mitchell Medical Student University of Louisville School of Medicine Email: jmmitc06@louisville.edu Faculty Mentor: Hunter N. Moseley, PhD Research Project: Developing computational tools for molecular comparison and metabolic placement of detectable uncharacterized metabolites



#### **Adam Morrison**

Undergraduate Student University of Louisville Email: <u>ajmorr03@cardmail.louisville.edu</u> Faculty Mentor: Jason Chesney, MD, PhD Research Project: Inhibition of glycolysis using a small molecule inhibitor PF158 in combination with temozolomide in melanoma cells



Jonathan A. Nitz Medical student University of Louisville School of Medicine Email: janitz01@louisville.edu Faculty Mentor: Jorge G. Gomez-Gutierrez, PhD Research Project: Enhancement of oncolytic adenovirus therapeutic efficacy by combination with temozolomide



Alan North Medical student University of Louisville School of Medicine Email: <u>anorth5@gmail.com</u> Faculty Mentor: Robert C. Martin, MD, PhD Research Project: Reflux related quality of life side effects in trans esophageal stenting for malignant obstruction



David D. Picklesimer Medical Student University of Louisville Email: <u>d0pick02@louisville.edu</u> Faculty Mentor: Lacey McNally, PhD Research Project: Pancreatic adenocarcinoma detected with targeted liposomes




#### Lauren Poole

University of Louisville Graduate Entering University of Louisville graduate student Email: <u>lgpool01@louisville.edu</u> Faculty Mentor: Gavin Arteel, PhD Research Project: The role of sinusoidal endothelial cells in the regulation of the innate immune response



**Douglas J. Saforo** University of Louisville undergrad Entering University of Louisville Medical Student Email: <u>djsafo01@louisville.edu</u> Faculty Mentor: J. Christopher States, PhD Research Project: Candidate drugs binding the Anaphase Promoting Complex: A novel target for anti-cancer therapy



**Tejas Sangoi** Undergraduate Student St. Louis University Email: <u>tsangoi@slu.edu</u> Faculty Mentor: Brian Ceresa, PhD Research Project: Endocytic trafficking of mutant epidermal growth factor receptors in lung cancer



**Sean P. Shannon** Medical student University of Louisville School of Medicine Email: <u>spshan01@louisville.edu</u> Faculty Mentor: Levi J. Beverly, PhD Research Project: Determining the role of normal and cancer-identified ubiquilin variants in altering cellular processes



Nicholas Siow Undergraduate Student Washington University Email: <u>N.SIOW@WUSTL.EDU</u> Faculty Mentor: John Trent, PhD Research Project: Automated G-quadruplex generation: From sequence to structure



Vanessa A. R. States University of Louisville undergrad Email: <u>vastat02@louisville.edu</u> Faculty Mentor: Susan Galandiuk, MD Research Project: Comparing target protein levels between non-neoplastic and sporadic CRC tissue based on dysregulated miRNAs



Amy Song Undergraduate Student Drexel University Email: <u>amy.song47@gmail.com</u> Faculty Mentor: Levi Beverly, PhD Research Project: Defining the biochemical determinants of BCLx1-induced leukemogenic potency



**Benjamin T. Turner** Medical student University of Louisville School of Medicine Email: <u>bentturner@gmail.com</u> Faculty Mentor: Susan Galandiuk, MD Research Project: Comparing microRNA levels between non-neoplastic and colon adenoma tissue



John R. Wehry Medical Student University of Louisville Email: jrwehr01@louisville.edu Faculty Mentor: Robert C. Martin, MD, PhD Research Project: Optimal management of metastatic neuroendocrine cancer to the liver: Concurrent therapy better than sequential management



Matthew R. Zeiderman Medical Student University of Louisville School of Medicine Email: <u>mzeid89@gmail.com</u> Faculty Mentor: Kelly McMasters, MD, PhD Research Project: Novel therapies for BRAFinhibitor resistant melanoma